

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2004232301 B2**

(54) Title
Selective spirocyclic glucocorticoid receptor modulators

(51) International Patent Classification(s)
A61K 31/00 (2006.01) **C07D 491/10** (2006.01)
A61K 31/415 (2006.01) **C07D 491/20** (2006.01)
C07D 231/54 (2006.01) **C07D 495/10** (2006.01)
C07D 487/10 (2006.01) **C07D 498/10** (2006.01)

(21) Application No: **2004232301** (22) Date of Filing: **2004.04.19**

(87) WIPO No: **WO04/093805**

(30) Priority Data

(31) Number (32) Date (33) Country
60/464,784 **2003.04.23** **US**

(43) Publication Date: **2004.11.04**

(44) Accepted Journal Date: **2009.11.12**

(71) Applicant(s)
Merck & Co., Inc.

(72) Inventor(s)
Colletti, Steven L.;Patel, Gool F.;Graham, Donald W.;Beresis, Richard;Ali, Amjad;Balkovec, James M.;Smith, Cameron J.

(74) Agent / Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market Street, Sydney, NSW, 2000

(56) Related Art
AU2003214879B
AU2003270783A
AU2003259802B
AU2003221706A
AU2004216182A

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/093805 A2

- (51) International Patent Classification⁷: **A61K** J. [AU/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: PCT/US2004/012102 (74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (22) International Filing Date: 19 April 2004 (19.04.2004) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/464,784 23 April 2003 (23.04.2003) US
- (71) Applicant (for all designated States except US): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ALI, Amjad** [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **BALKOVEC, James, M.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **BERESIS, Richard** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **COLLETTI, Steven, L.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **GRAHAM, Donald, W.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **PATEL, Gool, F.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **SMITH, Cameron,**
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS



(57) Abstract: The present invention encompasses compounds of Formula (I) and Formula (II) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

WO 2004/093805 A2

TITLE OF THE INVENTION

SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS

BACKGROUND OF THE INVENTION

5 Intracellular receptors (IR's) are a class of structurally related proteins involved in the regulation of gene expression. The steroid hormone receptors are a subset of this superfamily whose natural ligands are typically comprised of endogenous steroids such as estradiol, progesterone, and cortisol. Man-made ligands to these receptors play an important role in human health and, of these receptors, the glucocorticoid receptor has an essential role in regulating human physiology and immune response. Steroids that interact with the glucocorticoid receptor have been shown to be potent anti-inflammatory agents, although cross-reactivity with other steroid hormone receptors such as the mineralocorticoid, progesterone and androgen receptors can lead to problematic ancillary pharmacology.

10 The dissociation of transactivation from transrepression at the glucocorticoid receptor is believed to be an approach toward improving the side-effect profile related to steroid therapy. The beneficial anti-inflammatory activity of GR modulators, such as steroids, is believed to occur through the transrepression of genes encoding for proinflammatory cytokines, adhesion molecules and enzymes. Many of the undesirable side-effects associated with such agents are believed to occur through the transactivation, or induction, of gene transcription leading to the downstream perturbation of homeostatic endocrine function. Some of these affected metabolic processes include induced gluconeogenesis, induced amino acid degradation, osteoporosis, suppression of HPA axis, induction of secondary adrenal suppression, changes in electrolyte concentration, changes in lipid metabolism, growth retardation, impaired wound healing and skin thinning. Weak, partial and full agonism of GR related to transrepression and transactivation, including potential antagonism of the receptor regarding transactivation, may be applied to the treatment of inflammatory and autoimmune diseases such as

15 rheumatoid arthritis and asthma. For recent reviews see: (a) *Recent Advances in Glucocorticoid Receptor Action*; Cato, A.C.B., Schacke, H., Asadullah, K., Eds.; Springer-Verlag: Berlin-Heidelberg, Germany, 2002. (b) Coghlan, M.J.; Elmore, S.W.; Kym, P.R.; Kort, M.E. In *Annual Reports in Medicinal Chemistry*; Doherty, A.M., Hagmann, W.K., Eds.; Academic Press: San Diego, CA, USA, 2002; Vol. 37, Ch. 17, pp 167-176.


20 The present invention is directed to a novel class of compounds that are selective glucocorticoid receptor modulators that have potent anti-inflammatory and immunosuppressive activity and possess advantages over steroidal glucocorticoid ligands with respect to side effects, efficacy, toxicity and/or metabolism.

35

SUMMARY OF THE INVENTION

The present invention encompasses compounds of Formula I and Formula II:

5



I

II


or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid
 10 receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention encompasses compounds of Formula I and Formula

II:

15



I

II

20

or pharmaceutically acceptable salts or hydrates thereof, wherein

dotted lines represent the presence of either a single or double bonds;


m is 0, 1, 2 or 3,

n is 0, 1 or 2;

-A-B-C-D- is selected from the group consisting of:

- 5
- (1) -CH₂-CH₂-CH₂-O-,
- (2) -CH₂-CH₂-C(O)-O-,
- (3) -CH=CH-C(O)-O-,
- (4) -O-CH₂-CH₂-CH₂-,
- (5) -O-C(O)-CH₂-CH₂-,
- 10 (6) -HC=CH-CH₂-O-,
- (7) -CH₂-HC=CH-O-,
- (8) -CH₂-CH₂-C(O)-NH-,
- (9) -CH₂-NH-CH₂-CH₂-,
- (10) -CH₂-NH-C(O)-O-,
- (11) -NH-C(O)-NH-C(O)-,
- 15 (12) -C(O)-NH-C(O)-NH-,
- (13) -NH-C(O)-NH-CH₂-,
- (14) -NH-C(O)-NH-C(=S)-,
- (15) -O-CH₂-CH₂-O-,
- (16) -S-CH₂-CH₂-S-;
- 20

provided that when the atoms at positions B and C of -A-B-C-D- are both carbon atoms, said atoms may be joined together to form a ring selected from



25 X and Y are each independently selected from CH₂, S and O;

R¹ is selected from the group consisting of:

- (1) C₁₋₆alkyl,

- 5
- (2) C₂₋₆alkenyl,
 - (3) C₂₋₆alkynyl,
 - (4) C₃₋₆cycloalkyl,
 - (5) aryl,
 - (6) -CH₂-phenyl,
 - (7) HET,

wherein items (1) to (3) above are optionally substituted from one to three substituents independently selected from the group consisting of: halo, OR⁵, and NHR⁶, and items (4) to (7) are optionally substituted with from one to three substituents selected from the group consisting of: halo, OR⁵, NHR⁶, C₁₋₃alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl;

R² and R³ are each independently selected from the group consisting of:

- 15
- (1) hydrogen,
 - (2) halo,
 - (3) C₁₋₆alkyl,
 - (4) C₂₋₆alkenyl,
 - (5) C₂₋₆alkynyl,
 - (6) OR⁷,
 - (7) NHR⁸,
 - (8) aryl,
 - (9) -CH₂-phenyl;
- 20

R⁵, R⁶, R⁷ and R⁸ are each independently selected from the group consisting of:

- (1) hydrogen,
- (2) methyl;

25

each R⁴ is independently selected from the group consisting of

- (1) -OH,
 - (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, dimethylamino, =S, and halo,
 - (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O-C₁₋₂alkyl,
 - (4) C₂₋₆alkynyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,
- 30

5) phenyl optionally substituted with 1,2 or 3 substituents selected independently from hydroxy, C₁-2alkyl, -COOH, -C(O)-O-CH₃ and halo,

(6) -C₁-2alkyl-phenyl optionally substituted with 1,2 or 3 substituents independently selected from hydroxy, C₁-2alkyl and halo,

(7) -CO₂H,

(8) -CO₂C₁₋₃alkyl,

(9) -OC₁₋₃alkyl,

(10) -SO₂-C₁₋₃alkyl,

(11) -SO₂-phenyl optionally substituted with 1,2 or 3 substituents independently selected from hydroxy, C₁-2alkyl and halo

(12) -C₁₋₂alkyl-O-C₁₋₂alkyl,

(13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,

(14) -C₁₋₂alkyl-O-phenyl optionally substituted with with 1,2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,


(15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,

(16) 2-(1,3-dioxan)ethyl,

(17) -C₁₋₂alkyl-C(O)-NH-phenyl,

(18) -C₁₋₂alkyl-C(O)-NHN.

“with the proviso that the compound of Formula I or Formula II is



other than

”.

Within this aspect there is a genus of compounds wherein m is 0, 1 or 2.

Within this aspect, there is another genus of compounds wherein n is 0 or 1.

Within this aspect, there is another genus of compounds wherein R² and R³ are each individually hydrogen or methyl.

Within this aspect, there is another genus of compounds wherein each R⁴ is independently selected from the group consisting of

(1) -OH,

(2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, dimethylamino, thio, and halo,

- (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O-C₁₋₂alkyl,
- (4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
- 5 (5) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (6) -SO₂-C₁₋₃alkyl, and
- (7) -C₁₋₂alkyl-OC₁₋₂alkyl.


10

Within this aspect, there is another genus of compounds wherein R¹ is phenyl or pyridyl said phenyl or pyridyl or optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- 15 (a) halo,
- (b) OCH₃,
- (d) CH₃,
- (e) CN.

20 Within this genus, there is a sub-genus of compounds wherein R¹ is phenyl, optionally mono or di-substituted with halo.

Within this aspect there is a genus of compounds of Formula I wherein



25

I

m is 0, 1, 2 or 3;

n is 0 or 1;

R¹ is phenyl or pyridyl, said phenyl or pyridyl or optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- (a) halo,
- (b) OCH₃,
- (d) CH₃,
- (e) CN; and

5 R² and R³ are each individually hydrogen or methyl.

Within this genus, there is a sub-genus of compounds wherein each R⁴ is independently selected from the group consisting of

- (1) -OH,
- 10 (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, dimethylamino, thio, and halo,
- (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O-C₁₋₂alkyl,
- 15 (4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
- (5) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (6) -SO₂-C₁₋₃alkyl, and
- 20 (7) -C₁₋₂alkyl-OC₁₋₂alkyl.


Within this sub-genus, there is a class of compounds wherein

-A-B-C-D- is selected from the group consisting of:

- (1) -CH₂-CH₂-CH₂-O-,
- (2) -CH=CH-CH₂-O-,
- 25 (3) -CH₂-CH=CH-O-,
- (4) -O-CH₂-CH₂-CH₂-,
- (5) -O-CH₂-CH₂-O-,
- (6) -S-CH₂-CH₂-S-,
- (7) -CH₂-NH-CH₂-CH₂-, and
- 30 (8) -CH₂-NH-C(O)-O-;

R¹ is phenyl optionally mono or di- substituted with halo.

Within this aspect, there is a genus of compounds of Formula II



II

5 Wherein

 m is 0, 1 or 2;

 n is 0 or 1;

 R¹ is phenyl or pyridyl said phenyl or pyridyl or optionally mono or di- substituted with a substituent independently selected from the group consisting of:

10

 (a) halo,

 (b) OCH₃,

 (d) CH₃,

 (e) CN; and

 R² and R³ are each individually hydrogen or methyl.

15

 Within this genus, there is a sub-genus of compounds wherein each R⁴ is independently selected from the group consisting of -C₁₋₆alkyl or hydrogen;

20

 Within this genus, there is a subgenus of compounds wherein

 X and Y are both O or are both S or X is O and Y is CH₂;

 R¹ is phenyl optionally mono or di- substituted with halo.

25

 Another aspect of the invention encompasses a pharmaceutical composition comprising a compound of Formula I or Formula II in combination with a pharmaceutically acceptable carrier.

 Another aspect of the invention encompasses a method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising

administering the patient a compound of Formula I in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.

Within this aspect is encompassed the above method wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of: tissue rejection, leukemias, lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, obesity, metabolic syndrome, inflammatory bowel disease, systemic lupus erythematosus, polyarthritis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, juvenile rheumatoid arthritis, uveitis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, systemic lupus erythematosus, dermatomyositis, herpes gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type I reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitis, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, Human Immunodeficiency Virus (HIV), cell apoptosis, cancer, Kaposi's sarcoma, retinitis pigmentosa, cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome, schizophrenia, sleep disorders, and anxiety.

Another aspect of the invention encompasses a method of selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a mammal comprising administering to the mammal a compound of Formula I or Formula II in an amount that is effective to modulate the glucocorticoid receptor and minimizes side effects.

Exemplifying the invention are the compounds of the Examples disclosed hereunder.

The invention is described using the following definitions unless otherwise indicated.

The term "halogen" or "halo" includes F, Cl, Br, and I.

The term "alkyl" means linear or branched structures and combinations thereof, having the indicated number of carbon atoms. Thus, for example, C₁₋₆alkyl includes methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "alkoxy" means alkoxy groups of a straight, branched or cyclic configuration having the indicated number of carbon atoms. C₁₋₆alkoxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.

5 The term "alkylthio" means alkylthio groups having the indicated number of carbon atoms of a straight, branched or cyclic configuration. C₁₋₆alkylthio, for example, includes methylthio, propylthio, isopropylthio, and the like.

The term "alkenyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon double bond, wherein hydrogen may be replaced by an additional carbon-to-carbon double bond. C₂₋₆alkenyl, for example, includes
10 ethenyl, propenyl, 1-methylethenyl, butenyl and the like.

The term "alkynyl" means linear or branched structures and combinations thereof, of the indicated number of carbon atoms, having at least one carbon-to-carbon triple bond. C₃₋₆alkynyl, for example, includes , propenyl, 1-methylethenyl, butenyl and the like.

15 The term "cycloalkyl" means mono-, bi- or tri-cyclic structures, optionally combined with linear or branched structures, the indicated number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cycloheptyl, adamantyl, cyclododecylmethyl, 2-ethyl-1-bicyclo[4.4.0]decyl, and the like.

The term "aryl" is defined as a mono- or bi-cyclic aromatic ring system and includes, for example, phenyl, naphthyl, and the like.

20 The term "aralkyl" means an alkyl group as defined above of 1 to 6 carbon atoms with an aryl group as defined above substituted for one of the alkyl hydrogen atoms, for example, benzyl and the like.

The term "aryloxy" means an aryl group as defined above attached to a molecule by an oxygen atom (aryl-O) and includes, for example, phenoxy, naphthoxy and the like.

25 The term "aralkoxy" means an aralkyl group as defined above attached to a molecule by an oxygen atom (aralkyl-O) and includes, for example, benzyloxy, and the like.

The term "arylthio" is defined as an aryl group as defined above attached to a molecule by an sulfur atom (aryl-S) and includes, for example, thiophenoxy, thionaphthoxy and the like.

30 The term "aroyl" means an aryl group as defined above attached to a molecule by an carbonyl group (aryl-C(O)-) and includes, for example, benzoyl, naphthoyl and the like.

The term "aroyloxy" means an aroyl group as defined above attached to a molecule by an oxygen atom (aroyl-O) and includes, for example, benzoyloxy or benzyloxy, naphthoyloxy and the like.

35 The term "HET" is defined as a 5- to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, containing 1-4 heteroatoms selected from O, S and N, and optionally substituted with 1-2 oxo groups. Preferably, "HET" is a 5- or 6-membered aromatic or non-aromatic

monocyclic ring containing 1-3 heteroatoms selected from O, S and N, for example, pyridine, pyrimidine, pyridazine, furan, thiophene, thiazole, oxazole, isooxazole and the like, or HET is a 9- or 10-membered aromatic or partially aromatic bicyclic ring containing 1-3 heteroatoms selected from O, S, and N, for example, benzofuran, benzothiophene, indole, pyranopyrrole, benzopyran, quionoline, benzocyclohexyl, naphtyridine and the like. "HET" also includes the following: benzimidazolyl, benzofuranyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazoliny, quinolyl, quinoxaliny, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepiny, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranly, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinoliny, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranly, and tetrahydrothienyl.

The term "treating" encompasses not only treating a patient to relieve the patient of the signs and symptoms of the disease or condition but also prophylactically treating an asymptomatic patient to prevent the onset of the disease or condition or preventing, slowing or reversing the progression of the disease or condition. The term "amount effective for treating" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. The term also encompasses the amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.

The following abbreviations have the indicated meanings:

	AIBN	=	2,2'-azobisisobutyronitrile
30	9-BBN	=	9-borabicyclo[3.3.1]nonane
	B.P.	=	benzoyl peroxide
	Bn	=	benzyl
	CCl ₄	=	carbon tetrachloride
	DAST	=	diethylamine sulfur trifluoride
35	DCC	=	dicyclohexyl carbodiimide

	DCI	=	1-(3-dimethylaminopropyl)-3-ethyl carbodiimide
	DEAD	=	diethyl azodicarboxylate
5	Dess-Martin periodinane	=	[1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1 <i>H</i>)-one]
	DIBAL	=	diisobutyl aluminum hydride
	DME	=	ethylene glycol dimethylether
	DMAP	=	4-(dimethylamino)pyridine
	DMF	=	N,N-dimethylformamide
10	DMSO	=	dimethyl sulfoxide
	Et ₃ N	=	triethylamine
	HMPA	=	hexamethylphosphoramide
	HPLC	=	high performance liquid chromatography
	LCMS	=	tandem HPLC followed by MS
15	MS	=	mass spectrum (or mass spectroscopy)
	LDA	=	lithium diisopropylamide
	m-CPBA	=	metachloroperbenzoic acid
	NBS	=	N-bromosuccinimide
	NMR	=	nuclear magnetic resonance
20	NSAID	=	non-steroidal anti-inflammatory drug
	PCC	=	pyridinium chlorochromate
	PDC	=	pyridinium dichromate
	Ph	=	phenyl
	1,2-Ph	=	1,2-benzenediyl
25	Pyr	=	pyridine
	Qn	=	7-chloroquinolin-2-yl
	R ^s	=	-CH ₂ SCH ₂ CH ₂ Ph
	r.t.	=	room temperature
	rac.	=	racemic
30	THF	=	tetrahydrofuran
	THP	=	tetrahydropyran-2-yl
	TLC	=	thin layer chromatography

35 Alkyl group abbreviations

	Me	=	methyl
	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
5	n-Bu	=	normal butyl
	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl
	c-Pr	=	cyclopropyl
10	c-Bu	=	cyclobutyl
	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

Some of the compounds described herein contain one or more asymmetric centers and
15 may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend
such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and
pharmaceutically acceptable salts thereof.

Some of the compounds described herein contain olefinic double bonds, and unless
specified otherwise, are meant to include both E and Z geometric isomers.

20 The pharmaceutical compositions of the present invention comprise a compound of
Formula I or Formula II as an active ingredient or a pharmaceutically acceptable salt, thereof, and may
also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term
"pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic
bases including inorganic bases and organic bases. Salts derived from inorganic bases include
25 aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous,
potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium,
potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases
include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring
substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine,
30 choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine,
histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine,
polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine,
tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, 5 pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I or Formula II are meant to also include the pharmaceutically 10 acceptable salts.

The magnitude of prophylactic or therapeutic dose of a compound of Formula I or Formula II will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of Formula I or Formula II and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of 15 administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with the carrier materials to 20 produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain from about 0.5 mg to about 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 25 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

For the treatment of glucocorticoid receptor mediated diseases the compound of Formula I and Formula II may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, 30 intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, solutions, aqueous or oily suspensions, 35 dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Compositions

intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl

alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

5 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

10 The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions
15 may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the
20 known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or
25 polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of Formula I or Formula II may also be administered in the form of
30 suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing a
35 compound of Formula I or Formula II are employed. (For purposes of this application, topical

application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

5 The ability of the compounds of Formula I or Formula II to selectively modulate glucocorticoid receptors makes them useful for treating, preventing or reversing the progression of a variety of inflammatory and autoimmune diseases and conditions. Thus, the compounds of the present invention are useful to treat, prevent or ameliorate the following diseases or conditions: inflammation, tissue rejection, auto-immunity, various malianancies, such as leukemias and lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, 10 HPA axis suppression and regulation, hypercortisolemia, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, obesity and metabolic syndrome.

15 The compounds of the present invention are also useful for treating, preventing or reversing the progression of disease states involving systemic inflammation such as inflammatory bowel disease, systemic lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, juvenile rheumatoid arthritis, uveitis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's 20 disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, and cirrhosis.

The compounds of the present invention are useful for treating, preventing or reversing the progression of a variety of topical diseases such as inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, buflous pernphigoid, systemic lupus erythematosus, dermatomyositis, herpes 25 gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type I reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitis, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma.

30 The compounds of the present invention are also useful in treating, preventing or reversing the progression of disease states associated with Human Immunodeficiency Virus (HIV), cell apoptosis, and cancer including, but not limited to, Kaposi's sarcoma, immune system activation and modulation, desensitization of inflammatory responses, IIL- I expression, natural killer cell development, lymphocytic leukemia, and treatment of retinitis pigmentosa. Cognitive and behavioral processes are also 35 susceptible to glucocorticoid therapy where antagonists would potentially be useful in the treatment of

processes such as cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome, schizophrenia, stroke, sleep disorders, and anxiety.

The invention also encompasses a method for treating a glucocorticoid receptor mediated disease comprising concomitantly administering to a patient in need of such treatment a
5 compound of Formula I or Formula II and one or additional more agents. For treating or preventing asthma or chronic obstructive pulmonary disease, the compounds of Formula I or Formula II may be combined with one or more agents selected from the group consisting of: β -agonists (e.g., salmeterol), theophylline, anticholinergics (e.g., atropine and ipratropium bromide), cromolyn, nedocromil and leukotriene modifiers (e.g., montelukast). For treating or preventing inflammation, the compounds of
10 Formula I or Formula II may be combined with one or the following: a salicylate, including acetylsalicylic acid, a non-steroidal antiinflammatory drug, including indomethacin, sulindac, mefenamic, meclofenamic, tolfenamic, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen and oxaprozin, a TNF inhibitor, including etanercept and infliximab, an IL-1 receptor antagonist, including anakinra, a cytotoxic or immunosuppressive drug, including methotrexate,
15 leflunomide, azathioprine and cyclosporine, a gold compound, hydroxychloroquine or sulfasalazine, penicillamine, darbufelone, and a p38 kinase inhibitor. The compound of Formula I or Formula II may also be used in combination with bisphosphonates such as alendronate to treat a glucocorticoid mediated disease and simultaneously inhibit osteoclast-mediated bone resorption.


20

METHODS OF SYNTHESIS


The compounds of the invention are prepared by the following reaction schemes. All substituents are as defined above unless indicated otherwise.

25


Scheme 1




5 Scheme 2




Scheme 3



5 Scheme 4




Scheme 5




10


Scheme 6




5 Scheme 7




Scheme 8



5 Scheme 9




Scheme 10




10

Scheme 11




5


Scheme 12




10 Scheme 13




Scheme 14



5 Scheme 15




Scheme 16




10

Scheme 17




5

Scheme 18




10


Scheme 19




Scheme 20



5 Scheme 21




Scheme 22




5

Scheme 23




10

Scheme 24




5

Scheme 25




10

Scheme 26




5

Scheme 27



10

Scheme 28



5

REPRESENTATIVE EXAMPLES

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

(i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C;

(ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C;

(iii) the course of reactions was followed by TLC and/or LCMS and reaction times are given for illustration only;

(iv) the structure and purity of all final products were assured by at least one of the following techniques: TLC, HPLC, MS or NMR spectrometry;

(v) yields, when given, are for illustration only;

(vi) when line-listed, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 500 MHz or 600 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal;


(vii) chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (litre(s)), mL

(millilitres), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq or equiv (equivalent(s)), IC₅₀ (molar concentration which results in 50% of maximum possible inhibition), μ M (micromolar), nM (nanomolar).


5

PREPARATIVE EXAMPLESCOMPOUND A


10

Step 1:

15



4 Å molecular sieves (~5 g) and *p*-toluenesulfonic acid (5.34g, 28.05 mmol) were added to a solution of the Wieland-Miescher ketone (5 g, 28.05 mmol) in ethylene glycol (140 mL). After stirring at room temperature for 23 min., the reaction was poured slowly into a 2:1 mixture of ice water/sat. aqueous NaHCO₃ (150 mL). The reaction was extracted with EtOAc (4 x 100 mL) and the combined organic layers were washed with brine (100 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (0 to 40% EtOAc/hexanes) on silica gel to afford the ketal (5.77g, 93%) as a white solid. LCMS = 223; (M + 1)⁺. ¹H NMR (CDCl₃, 500 MHz): δ 5.83 (br d, *J* = 1.8 Hz, 1H), 4.43-3.94 (m, 4H), 2.49-2.40 (m, 3H), 2.39-2.27 (m, 2H), 1.95-1.88 (m, 1H), 1.84-1.78 (m, 1H), 1.76-1.64 (m, 3H), 1.37 (s, 3H).

Step 2:


15

Ethyl formate (7.36 mL, 86.48 mmol) and sodium hydride (60% suspension in mineral oil; 3.46 g, 86.48 mmol) were added to a cooled solution (-40 °C) the ketal in anhydrous benzene (200 mL). MeOH (450 TL) was added dropwise over 15 min. and the reaction allowed to warm to room temperature. After stirring for 3 h, the reaction was cooled to 0 °C and water (50 mL) was added. The biphasic system was shaken and the organic layer was washed with water (3 x 50 mL). The combined aqueous layers were washed with diethyl ether (100 mL) and then acidified to pH 5.5-6 with sat. aqueous KH₂PO₄. The aqueous layer was extracted with EtOAc (5 x 200 mL). The combined extracts were dried (Na₂SO₄) and concentrated *in vacuo* to afford the hydroxyketone (5.04 g, 93%) as an orange oil. LCMS = 251; (M + 1)⁺.

25


30

Step 3:



The hydroxyketone (4.1 g, 16.4 mmol) was dissolved in glacial acetic acid (40 mL) and *p*-
 5 fluorophenylhydrazine hydrochloride (2.8 g, 17.22 mmol) and sodium acetate (1.41 g, 17.22 mmol)
 were added. After stirring at room temperature for 2 h, the reaction was poured slowly into 10%
 NaHCO₃ (1 L) and extracted with EtOAc (6 x 500 mL). The combined extracts were washed with
 brine (500 mL), dried (MgSO₄) and concentrated *in vacuo*. The crude material was purified by flash
 chromatography (10% EtOAc/hexanes) on silica gel to afford **EXAMPLE 138** (2.26 g, 41%) as an
 10 orange solid. LCMS = 421; (M + 1)⁺. ¹H NMR (CDCl₃, 500 MHz): δ 7.47-7.44 (m, 2H), 7.43 (s,
 1H), 7.18-7.16 (d, *J* = 8.5 Hz, 1H), 7.16-7.14 (d, *J* = 8.7 Hz, 1H), 6.22 (br d, *J* = 2.2 Hz, 1H), 4.11-
 4.01 (m, 4H), 3.20-3.16 (d, *J* = 15.7 Hz, 1H), 2.54-2.51 (d, *J* = 16 Hz, 1H), 2.51-2.40 (m, 1H), 2.34-
 2.28 (m, 1H), 1.88-1.64 (m, 4H), 1.23 (s, 3H).

15 Step 4:




EXAMPLE 138 (2.26 g; 6.65 mmol) was dissolved in THF (65 mL) and 6N HCl (4.43 mL, 26.6
 20 mL) was added. The reaction was heated at 65 °C for 3.5 h and then poured slowly into 10%
 NaHCO₃ (150 mL). The mixture was extracted with EtOAc (4 x 250 mL) and the combined extracts
 washed with brine (2 x 200 mL), dried (MgSO₄) and concentrated *in vacuo* to afford **COMPOUND**
A (1.97 g, 100%) as a brown oil. LCMS = 297; (M + 1)⁺. ¹H NMR (CDCl₃, 500 MHz): δ 7.50 (s,
 1H), 7.49-7.45 (m, 2H), 7.20-7.16 (m, 2H), 6.31 (br d, *J* = 2 Hz, 1 H), 2.96-2.88 (m, 2H), 2.72-2.62

(m, 2H), 2.59-2.53 (m, 2H), 2.14-2.80 (m, 1H), 1.75-1.64 (qt, $J = 13.1$ Hz, $J = 4.3$ Hz, 1H), 1.27 (s, 3H).

COMPOUND B

5



COMPOUND B was prepared from the known Hajos-Parrish ketone (*J. Org. Chem.* **1974**, *39*(12), 1612-1621.) following the same reaction sequence and procedure described above for the preparation of **COMPOUND A**.


10

EXAMPLES

15

The following examples illustrate the preparation of some of the compounds of the invention and are not to be construed as limiting the invention disclosed herein.

EXAMPLE 1




20

In 2 mL of anhydrous degassed tetrahydrofuran under an argon atmosphere were added tris(dibenzylideneacetone) dipalladium (0) (10 mg), triphenyl phosphine (30 mg) and trimethyl tin acetate (20 mg). To this was added **COMPOUND A** (110 mg, 0.374 mmol) in 1.0 mL degassed THF followed by trimethylsilyl acetoxy propene. The resulting reaction mixture was heated to 100 °C for 15 h

in a sealed tube before being filtered through celite, washed with ethyl acetate (50 mL) and evaporated under reduced pressure. The crude reaction mixture was purified by column chromatography (SiO₂, acetone/hexanes) to give recovered starting material (58 mg) and desired product as a white foam. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 351 (M⁺+1)).

5


EXAMPLE 2



EXAMPLE 1 (10 mg, 0.029 mmol) was diluted into ethyl acetate (1 mL), treated with a catalytic amount of palladium on carbon, and exposed to an atmosphere of hydrogen gas via a double-walled balloon; vacuum-purged thrice. The reaction mixture was stirred at room temperature for 1 h, filtered over celite and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (SiO₂, 250 micron, 20X20 cm, 30% EtOAc-hexanes) to give the desired product as a mixture of isomers which was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 353 (M⁺+1)).

15

EXAMPLE 3




EXAMPLE 1 (10 mg, 0.029 mmol) was diluted into (1:1) THF-H₂O (1 mL), treated with mercury(II) acetate (14 mg, 0.043 mmol), and the reaction mixture stirred at 23 °C for 14 h. The reaction mixture was then treated slowly with 0.50 mL of a solution of sodium borohydride (56 mg, 1.5 mmol) in aqueous 3M NaOH at room temperature. The reaction mixture was maintained for 2 h at 23 °C, partitioned between


water and diethyl ether, the organic phase dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (SiO₂, 250 micron, 20X20 cm, 50% EtOAc-hexanes) to give the separated isomeric products, each of which were characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 369 (M⁺+1)).

5

EXAMPLES 4 AND 5



EXAMPLE 4




EXAMPLE 5

10

COMPOUND A (50 mg, 0.168 mmol) was dissolved in 1.0 mL of THF under argon atmosphere. Activated zinc (0.336 mmol, 22 mg), ethyl α -bromomethyl acrylate (0.336 mmol, 0.040 mL), and catalytic hydroquinone (0.005 mL) were added and the reaction mixture was heated to 110 °C for 15 hours before it was cooled to room temperature. The reaction was quenched with 25 mL of 1 N aqueous HCl, extracted with methylene chloride (3 x 25 mL) and the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction mixture was purified by column chromatography (SiO₂, ethyl ether/hexanes) to give the desired isomeric products as white foams. The product isomers were each characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 365 (M⁺+1)).

20


EXAMPLE 6



5 **COMPOUND A** (300 mg, 1.0 mmol) was dissolved in 4 mL of anhydrous THF under argon atmosphere and cooled to $-50\text{ }^{\circ}\text{C}$. Then 3.0 equiv of allyl magnesium bromide (1M in THF, 3.00 mmol, 3.0 mL) was added dropwise. The resulting reaction mixture was then allowed to slowly warm to $23\text{ }^{\circ}\text{C}$ over 6 h. The reaction was quenched with 50 mL of saturated aqueous NH_4Cl , extracted with methylene chloride (3 x 35 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction mixture was purified by flash column chromatography (SiO_2 , EtOAc/hexanes) to give
10 the desired product as an off-white foam. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 339 (M^++1)).

15


EXAMPLE 7



20


EXAMPLE 7 was prepared from **COMPOUND A** according to the above procedure described in **EXAMPLE 6**. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 353 (M^++1)).

5

EXAMPLE 8


EXAMPLE 8 was prepared from **COMPOUND B** according to the above procedure described in **EXAMPLE 6**. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 339 (M^++1)).

10

EXAMPLE 9


15 **EXAMPLE 6** (50 mg, 0.148 mmol) was dissolved in 1.0 mL of 5:1 THF/HMPA under argon atmosphere and sodium hydride (60% in mineral oil, 0.290 mmol, 12 mg) was added and the reaction mixture was allowed to stir for 10 min at room temperature. Allyl bromide (0.592 mmol, 0.051 mL) was then added and the reaction was heated to 80 °C for 2 hours before cooling to room temperature. The reaction was then quenched by the addition of 25 mL of saturated aqueous NH_4Cl , extracted with methylene chloride
20 (3 x 25 mL) and the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction mixture was purified by column chromatography (SiO_2 , acetone/hexanes) to give the desired product as a pale yellow foam. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 379 (M^++1)).

EXAMPLE 10



- 5 **EXAMPLE 10** was prepared from **EXAMPLE 6** according to the above procedure described in **EXAMPLE 9**. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 437 (M^++1)).

EXAMPLE 11




10

- EXAMPLE 11** was prepared from **EXAMPLE 6** according to the above procedure described in **EXAMPLE 9**. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 393 (M^++1)).


15

EXAMPLE 12




EXAMPLE 9 (8 mg, 0.021 mmol) was dissolved in 1.0 mL of degassed benzene under argon
5 atmosphere and to this was added catalytic bis(tricyclohexylphosphine)-benzylidene ruthenium (IV)
dichloride (2 mg) and the resulting reaction mixture was heated to 100 °C for 4 hours before it was
cooled to room temperature, filtered through celite, washed with ethyl acetate (25 mL) and evaporated
under reduced pressure. The crude reaction mixture was purified by column chromatography (SiO₂,
acetone/hexanes) to give the desired product as a clear film. The product was characterized by ¹H NMR,
10 HPLC and mass spectroscopy (m/z: 351 (M⁺+1)).

EXAMPLE 13




15 EXAMPLE 13 was prepared from EXAMPLE 11 according to the above procedure described in
EXAMPLE 12. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 365
(M⁺+1)).

EXAMPLE 14



EXAMPLE 14 was prepared from EXAMPLE 10 according to the above procedure described in
5 EXAMPLE 12. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 409 (M^++1)).

EXAMPLE 15




10

EXAMPLE 15 was prepared via a lithium aluminum hydride reduction of EXAMPLE 14 according to the procedure described below in EXAMPLE 78. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 381 (M^++1)).

15


20

EXAMPLE 16



5 **EXAMPLE 7** (14 mg, 0.039 mmol) was dissolved in 1.0 mL THF under argon atmosphere and cooled to 0 °C and 9-borabicyclo[3.3.1]nonane (0.5M in THF, 0.156 mmol, 0.312 mL) was added. The reaction mixture was allowed to warm to room temperature and stir for 15 h before being quenched by the addition of 1 mL of ethanol, 0.052 mL of 6N aqueous NaOH, and 0.1 mL of 30% aqueous hydrogen peroxide. The reaction mixture was then diluted with 5.0 mL of water, extracted with methylene
10 chloride (3 x 4 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by preparative thin layer chromatography (SiO₂, EtOAc/hexanes) and characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 371 (M⁺+1)).

EXAMPLE 17




15

EXAMPLE 17 was prepared from **EXAMPLE 8** according to the above procedure described in **EXAMPLE 16**. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 357 (M⁺+1)).


20

EXAMPLE 18



5 **EXAMPLE 16** (15 mg, 0.041 mmol) was dissolved in 1.0 mL methylene chloride under argon atmosphere and cooled to 0 °C before 20 equiv of pyridine (0.82 mmol, 0.066 mL) and 3.0 equiv of Dess-Martin periodinane (0.122 mmol, 52 mg) were added, and the reaction mixture was then warmed to room temperature over 15 h. The reaction mixture was quenched with 20 mL of saturated aqueous NH₄Cl, extracted with methylene chloride (3 x 15 mL), and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by column chromatography (SiO₂, EtOAc/hexanes) and characterized by ¹H NMR, HPLC and mass spectroscopy
10 (m/z: 367 (M⁺+1)).

EXAMPLE 19




15

EXAMPLE 19 was prepared from **EXAMPLE 17** according to the above procedure described in **EXAMPLE 18**. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 355 (M⁺+1)).

20

EXAMPLE 20




5

EXAMPLE 18 (6 mg, 0.016 mmol) was dissolved in 0.5 mL methylene chloride under argon atmosphere and cooled to -80 °C before triethyl silane (0.163 mmol, 0.027 mL) and boron trifluoride etherate (0.049 mmol, 0.007 mg) were added and the reaction mixture was then allowed to slowly warm to 0 °C. The reaction was quenched with 20 mL of saturated aqueous sodium bicarbonate, extracted with methylene chloride (3 x 15 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography (SiO₂, acetone/hexanes) to give the desired product as a clear film. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 353 (M⁺+1)).


15

EXAMPLE 21



EXAMPLE 21 was prepared from **EXAMPLE 19** according to the above procedure described in **EXAMPLE 20**. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 339 (M⁺+1)).


EXAMPLE 22



5 **EXAMPLE 18** was dissolved in 0.5 mL of methylene chloride under argon atmosphere and cooled to –
80 °C. To this was added boron trifluoride etherate (0.105 mmol, 0.013 mL) and dimethyl zinc [1M
heptane] (0.21mmol, 0.21 mL) and the reaction mixture was allowed to warm to room temperature and
stir for 15 h. The reaction was quenched with 10 mL of saturated aqueous ammonium chloride, extracted
with methylene chloride (3 x 10 mL), and the organic layers were dried over sodium sulfate and
10 evaporated under reduced pressure. The residue was purified by column chromatography (SiO₂,
acetone/hexanes) to give the desired product as a clear film. The product was characterized by ¹H NMR,
HPLC and mass spectroscopy (m/z: 367 (M⁺+1)).


EXAMPLE 23

15




EXAMPLE 23 was prepared from **EXAMPLE 18** according to the above procedure described in
EXAMPLE 22. The product was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 381
20 (M⁺+1)).

EXAMPLE 24



5 **EXAMPLE 24** was prepared from **EXAMPLE 19** according to the above procedure described in **EXAMPLE 22**. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 353 (M^++1)).

EXAMPLE 25




10

COMPOUND A (300 mg, 1.01 mmol) was diluted into THF (10 mL), treated with allyl methyl ether (0.318 mL, 3.4 mmol), and *t*-butyl lithium (1.8 mL, 3 mmol) at -78 °C and maintained for 1 h. The reaction mixture was then partitioned between $\text{NH}_4\text{Cl}_{(\text{aq})}$ and CH_2Cl_2 . The organic phase was dried over
15 anhydrous sodium sulfate and concentrated in vacuo. The crude product was either used directly in subsequent reactions or purified by flash chromatography (Biotage 40S, SiO_2 , 30% EtOAc-hexane) to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 369 (M^++1)).

20

EXAMPLE 26




5

EXAMPLE 25 (372 mg, 1.01 mmol) was diluted into a solution of tetrahydrofuran (20 mL) and 3N perchloric acid (3 mL). The mixture was maintained at room temperature for 15 h. The reaction mixture was concentrated in vacuo and purified by preparative thin layer chromatography (4 X 1500 micron SiO₂, 20X20 cm, 30% acetone-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 355 (M⁺+1)).

10

EXAMPLE 27




EXAMPLE 26 (45 mg, 0.13 mmol) was diluted into CH₂Cl₂ (6.5 mL) and treated with 4-methylmorpholine *N*-oxide (45.6 mg, 0.39 mmol) and activated 4Å sieves. The reaction mixture was then cooled to 0 °C and treated with tetrapropylammonium perruthenate (4.6 mg, 0.013 mmol), maintained at 23 °C for 1 h, filtered over celite and partitioned between 10% NaHSO_{3(aq)} and CH₂Cl₂. The organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative thin layer chromatography (1500 micron SiO₂, 20X20 cm, 50% EtOAc-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 353 (M⁺+1)).

15


20

EXAMPLE 28



5 **EXAMPLE 26** (47 mg, 0.12 mmol) was diluted into CH_2Cl_2 (6.5 mL), cooled to -78°C , and treated with triethylsilane (0.198 mL, 1.2 mmol) and boron trifluoride diethyl etherate (0.031 mL, 0.24 mmol). The reaction mixture was maintained at -78°C for 0.5 h and then warmed to 23°C for 1 h. The mixture was partitioned between $\text{NaHCO}_3(\text{aq})$ and CH_2Cl_2 , the organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative thin layer chromatography (1500 micron SiO_2 , 20X20
10 cm, 50% EtOAc-hexane) to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 339 (M^++1)).

EXAMPLE 29




15

EXAMPLE 27 (47 mg, 0.12 mmol) was diluted into tetrahydrofuran (0.355 mL), cooled to -78°C , treated with lithium bis(trimethylsilyl)amide (0.146 mL, 0.146 mmol, 1M THF), and maintained at -78°C for 0.5 h. The reaction mixture was treated with benzyl bromide (0.042 mL, 0.35 mmol) and maintained at 0°C for 3 h. The mixture was partitioned between $\text{NaHCO}_3(\text{aq})$ and EtOAc, the organic
20 phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative thin

layer chromatography (500 micron SiO₂, 20X20 cm, 30% acetone-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 533 (M⁺+1)).

EXAMPLE 30




5


EXAMPLE 29 (60 mg, 0.11 mmol) was diluted into toluene (0.550 mL), then cooled to -78 °C, treated with diisobutylaluminum hydride (0.230 mL, 0.23 mmol, 1M toluene), and maintained at -78 °C for 1 h. The reaction mixture was quenched with Rochelle's salt (2.75 mL) and filtered over celite. The mixture was partitioned between NaHCO_{3(aq)} and CH₂Cl₂, the organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative thin layer chromatography (500 micron SiO₂, 20X20 cm, 30% acetone-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 535 (M⁺+1)).

10

EXAMPLE 31




EXAMPLE 30 (20 mg, 0.037 mmol) was diluted into CH_2Cl_2 (0.748 mL), cooled to -78°C and treated with allyltrimethylsilane (0.059 mL, 0.374 mmol) and boron trifluoride diethyl etherate (0.009 mL, 0.075 mmol). The reaction mixture was maintained at -78°C for 0.5 h and warmed to 23°C for 3 h. The mixture was partitioned between $\text{NaHCO}_3(\text{aq})$ and CH_2Cl_2 , the organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative thin layer chromatography (500 micron SiO_2 , 20X20 cm, 30% acetone-hexane) to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 559 (M^++1)).

EXAMPLE 32


COMPOUND B (330 mg, 1.06 mmol) in THF (10 mL) was added dropwise to a solution of allyl magnesium bromide (6.21 mL, 6.21 mmol) in THF (10 mL). The reaction mixture was maintained at 23°C for 1 h, partitioned between $\text{NH}_4\text{Cl}(\text{aq})$ and CHCl_3 , the organic phase dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was used in the subsequent reaction to generate **EXAMPLE 33**. The product was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 325 (M^++1)).

15

EXAMPLE 33


EXAMPLE 32 (131 mg, 0.404 mmol) was diluted into tetrahydrofuran (4 mL) and treated with 9-BBN (4.04 mL, 2.02 mmol). The reaction mixture was maintained at 23 °C for 1 h, quenched with ethanol (4.04 mL), 30% sodium hydroxide (1.21 mL), and 60% hydrogen peroxide (2.42 mL) respectively. The quenched reaction mixture was maintained at 50 °C for 1 h. The mixture was then partitioned between
5 H₂O and CH₂Cl₂. The organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO₂, 1:9:90 NH₄OH-MeOH-CHCl₃) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 343 (M⁺+1)).

10

EXAMPLE 34

EXAMPLE 33 (113 mg, 0.343 mmol) was diluted into CH₂Cl₂ (8 mL) and treated with 4-methylmorpholine *N*-oxide (91.44 mg, 0.78 mmol) and activated 4A sieves. The reaction mixture was
15 then cooled to 0 °C and treated with tetrapropylammonium perruthenate (10.98 mg, 0.031 mmol). The reaction mixture was maintained at 23 °C for 1 h, filtered over celite, and partitioned between 10% NaHSO_{3(aq)} and CH₂Cl₂. The organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by preparative reversed phase HPLC (C18 SiO₂, 0-100% acetonitrile gradient in water with 0.1% TFA eluent) to provide the product which was characterized by ¹H NMR, HPLC and
20 mass spectrometry (m/z: 339 (M⁺+1)).

EXAMPLE 35




5

EXAMPLE 35 WAS PREPARED FROM EXAMPLE 34 ACCORDING TO THE ABOVE PROCEDURE DESCRIBED IN EXAMPLE 29. THE PRODUCT WAS CHARACTERIZED BY ^1H NMR, HPLC AND MASS SPECTROSCOPY (M/Z : 419 (M^++1)).

10

EXAMPLE 36




15

EXAMPLE 35 (33 mg, 0.079 mmol) was diluted into EtOAc (3 mL) and treated with palladium on carbon under one atmosphere of $\text{H}_{2(g)}$ (double-walled balloon). The reaction mixture was maintained at 23 °C for 0.5 h, filtered over celite, concentrated in vacuo, and purified by preparative centrifugal thin layer chromatography (Chromatotron, 2mm SiO_2 , 10% to 50% ethyl acetate-hexane gradient elution) to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 423 (M^++1)).


20

EXAMPLE 37



Magnesium turnings (10 mg, 0.42 mmol) were crushed and dissolved in THF (1 mL). Bromoethane
 5 (0.031 mL, 0.42 mmol) was added dropwise to the solution and allowed to stir at 23 °C for 0.5 h. The mixture was cooled to 0 °C, treated with propargyloxytrimethylsilane (0.064 mL, 0.42 mmol), and warmed to 23 °C for 0.5 h. **COMPOUND A** (100 mg, 0.34 mmol) in THF (0.5 mL) was diluted into the above described solution at 0 °C and maintained at 23 °C for 1.5 h. The reaction mixture was partitioned
 10 in vacuo, and the crude diol was used directly in the subsequent reaction to generate **EXAMPLE 38**. The product was characterized by ¹H NMR, HPLC and mass spectrometry (*m/z*: 353 (*M*⁺+1)).


EXAMPLE 38



15


EXAMPLE 37 (20 mg, 0.056 mmol) was diluted into dioxane (0.2 mL), and the mixture was treated
 with bis(triphenylphosphine)palladium dichloride (40 mg, 0.056 mmol) and tributyltin hydride (0.450
 mL, 2.24 mmol). The mixture was maintained at 0 °C for 3 h, filtered over celite, concentrated in vacuo,
 and purified by preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO₂, 1%
 20 triethylamine-ethyl acetate) to provide the product which was characterized by ¹H NMR, HPLC and mass
 spectrometry (*m/z*: 645 (*M*⁺+1)).

EXAMPLE 39



5 **EXAMPLE 38** (11 mg, 0.017 mmol) was diluted into tetrahydrofuran (0.010 mL), treated with triphenylphosphine (9.12 mg, 0.030 mmol), cooled to 0 °C, and then treated with diethyl azodicarboxylate (0.005 mL, 0.030 mmol). The mixture was maintained at 0 °C for 1 h, concentrated in vacuo, and purified by preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO₂, 1% triethylamine-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass
10 spectrometry (m/z: 627 (M⁺+1)).

EXAMPLES 40 AND 41



EXAMPLE 40

EXAMPLE 41

15


EXAMPLES 40 and 41 were prepared by diluting **EXAMPLE 39** (13 mg, 0.020 mmol) in toluene (1 mL) and treating the solution with lithium chloride (2.5 mg, 0.059 mmol), bromobenzene (0.003 mL, 0.029 mmol), and tetrakis-(triphenylphosphine)-palladium (1 mg, 0.0004 mmol). The reaction mixture was heated at 100 °C for 15 h, cooled to room temperature, filtered over celite, concentrated in vacuo,
20 and purified by preparative thin layer chromatography (250 micron SiO₂, 20X20 cm, 20% acetone-

hexane) to provide the resolution of both products which were each characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 413 (M^++1)).

5 EXAMPLES 42-47


The following compounds were prepared under conditions similar to those described in the examples above and illustrated in Scheme 10. Other bromides known to those skilled in the art were used in place of bromobenzene to generate the analogs shown in the table below. Hydrogenation of **EXAMPLE 46** as described in **EXAMPLE 36** was used to generate **EXAMPLE 47**. The following examples were

10 characterized by ^1H NMR, HPLC and mass spectrometry.



EXAMPLE	n	R-Group	MS (m/z) (M^++1)
42	1	vinyl	349
43	1	phenyl	399
44	1	4-fluorophenyl	417
45	2	benzyl	427
46	2	vinyl	363
47	2	ethyl	365


EXAMPLE 48



5 **EXAMPLE 41** (113 mg, 0.343 mmol) was diluted into dichloroethane (0.436 mL) and treated with triethylsilane (0.072 mL, 0.436 mmol) and trifluoroacetic acid (0.010 mL, 0.1309 mmol). The reaction mixture was maintained at 60 °C for 15 h, concentrated in vacuo, purified by preparative thin layer chromatography (250 micron SiO₂, 20X20 cm, 30% EtOAc-hexane) and then preparative HPLC (CHIRALPAK AD column, 4% ethanol-heptane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 415 (M⁺+1)).

10

EXAMPLE 49




15 **COMPOUND B** was converted into a propargylic diol according to the above procedure described in **EXAMPLE 37**. This intermediate (50 mg, 0.148 mmol) was diluted into acetone (2 mL), treated with quinoline (0.010 mL, 0.093 mmol), Lindlar catalyst (15 mg), and the reaction mixture vacuum-purged with hydrogen gas via a double-walled balloon. The reaction mixture was maintained under a hydrogen atmosphere for 15 h at 23 °C, filtered over celite and concentrated in vacuo. The crude allylic diol (50 mg, 0.148 mmol) was diluted into methylene chloride (1 mL), treated with activated 4A powdered sieves, NMO (86 mg, 0.74 mmol) and catalytic TPAP (10 mg, 0.029 mmol). The reaction mixture was stirred at
20 room temperature for 14 h, filtered over celite, partitioned between 10% aqueous NaHSO₃ and CH₂Cl₂,

the organic phase washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by preparative reversed phase HPLC (C18 SiO₂, 0-100% acetonitrile gradient in water with 0.1% TFA eluent) to provide the product hydroxyenal. This intermediate (10 mg, 0.030 mmol) was diluted into *tert*-butanol (0.50 mL), and 2-methyl-2-butene (0.74 mmol, 0.10 mL) was added. 5 The reaction mixture was allowed to stir for 5 min at 23 °C, and then a solution of sodium chlorite (0.089 mmol, 8 mg) and mono-basic sodium phosphate (0.074 mmol, 11 mg) in 0.20 mL of H₂O was added. The reaction mixture was allowed to stir for 13 h at 23 °C, and then quenched with saturated aqueous NH₄Cl, extracted with methylene chloride, and the organic phase dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (250 10 micron SiO₂, 20X20 cm, 30% EtOAc-hexane) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 337 (M⁺+1)).

EXAMPLES 50-70

15 The following compounds were prepared under conditions similar to those described in the examples above and illustrated in Schemes 5-9. The following examples were characterized by ¹H NMR, HPLC and mass spectrometry.




20

EX.	n	X	Y	Z	R ₁	R ₂	MS (m/z) (M ⁺ +1)
50	1	O	CH ₂	CH ₂	propyl	propyl	409
51	1	O	CH ₂	CHOH	propyl	propyl	425

52	1	O	CH ₂	CH ₂	allyl	allyl	405
53	1	O	CH ₂	CHOH	allyl	allyl	421
54	1	O	CH ₂	CH ₂	methyl	methyl	353
55	1	O	CH ₂	CHOH	methyl	methyl	369
56	1	O	CH ₂	C(O)	methyl	methyl	367
57	1	O	CH ₂	CH ₂	H	H	325
58	1	O	CH ₂	CHOH	H	H	341
59	2	CH ₂	O	CH ₂	ethyl	H	367
60	2	CH ₂	O	CH ₂	H	ethyl	367
61	2	CH ₂	O	CH ₂	H	phenyl	415
62	2	O	CH ₂	CH(allyl)	allyl	allyl	459
63	2	O	CH ₂	CH ₂	methyl	methyl	367
64	2	O	CH ₂	CH ₂	benzyl	benzyl	519
65	2	O	CH ₂	CH ₂	allyl	allyl	419
66	2	O	CH ₂	CHOH	methyl	methyl	383
67	2	O	CH ₂	CHOH	allyl	allyl	435
68	2	O	CH ₂	CH(allyl)	H	H	379


69	2	O	CH ₂	C(O)	methyl	methyl	381
70	2	O	CH ₂	C(O)	allyl	allyl	433

EXAMPLE 71



5 **COMPOUND B** (100 mg, 0.35 mmol) was diluted into pyridine (1 mL) and treated with hydroxylamine hydrochloride (28.06 mg, 0.40 mmol). The reaction mixture was maintained at 90 °C for 2 h, then partitioned between 0.1N HCl and CH₂Cl₂. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was used directly in the subsequent reaction to generate **EXAMPLE 72**. The product which was characterized by HPLC and mass spectrometry (m/z: 298
10 (M⁺+1)).

EXAMPLE 72




15 In an ice bath, **EXAMPLE 71** (526 mg, 1.77 mmol) was diluted into a 0 °C solution of *N*-bromosuccinimide (1 g, 5.62 mmol), potassium bicarbonate (556.45 mg, 5.55 mmol), H₂O (1 mL), and dioxane (6.33 mL). The reaction mixture was maintained at 0 °C for 48 h. After 48 h, the reaction mixture was treated with sodium borohydride (207.57 mg, 5.49 mmol). The reaction mixture was maintained at 23 °C for 0.5 h. The mixture was then partitioned between NH₄Cl_(aq) and CH₂Cl₂, and the organic phase was dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by

preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO₂, 10% to 60% ethyl acetate-hexane gradient elution) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 314 (M⁺+1)).

5


EXAMPLE 73



10

EXAMPLE 72 (4 mg, 0.013 mmol) was diluted into *tert*-butyl alcohol (0.036 mL), treated with methyl acrylate (0.69 mL, 0.77 mmol) and then Triton B (0.018 mL, 0.040 mmol). The reaction mixture was maintained at 23 °C for 15 h and then concentrated in vacuo. The crude reaction product, which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 400 (M⁺+1)), was used directly in the subsequent reaction to generate **EXAMPLE 74**.

EXAMPLE 74




15

EXAMPLE 73 (6 mg, 0.021 mmol) was diluted into glacial acetic acid (0.5 mL) and treated with zinc dust (22 mg, 6.8 mmol). The mixture was maintained at 25 °C for 15 h, filtered over celite and washed with CH₂Cl₂. The filtrate was concentrated in vacuo and purified by preparative reversed phase HPLC (C18 SiO₂, 0-100% acetonitrile gradient in water with 0.1% TFA eluent) to provide the product which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 338 (M⁺+1)).


20

EXAMPLE 75



A THF (9 mL) solution of *tert*-butyl acetate (0.72 mL, 5.32 mmol) was treated with lithium hexamethyldisilazane (6.2 mL, 6.21 mmol, 1M THF) at $-78\text{ }^{\circ}\text{C}$ and the mixture aged for 15 min. The ester enolate was then treated with a THF (9 mL) solution of **COMPOUND B** (500 mg, 1.77 mmol), the mixture aged 30 min at $-78\text{ }^{\circ}\text{C}$, maintained 11 h at room temperature, and then quenched with water, partitioned with ethyl acetate, the organic phase dried over anhydrous sodium sulfate, and concentrated in vacuo. This beta-hydroxy ester intermediate was vacuum pumped dry, and the crude residue diluted into CHCl_3 (18 mL), cooled to $0\text{ }^{\circ}\text{C}$, treated with Martin Sulfurane reagent (3.6 g, 5.32 mmol), and the reaction mixture was stirred at $0\text{ }^{\circ}\text{C}$ for 3 h. The reaction mixture was warmed to $23\text{ }^{\circ}\text{C}$, partitioned between $\text{NaHCO}_{3(\text{aq})}$ and CHCl_3 , the organic phase dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO_2 , 0% to 20% ethyl acetate-hexane gradient elution) to provide the product as a (3:2) mixture of double bond isomers which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 381 (M^++1)).


EXAMPLE 76



EXAMPLE 75 (670 mg, 1.77 mmol) was diluted into methylene chloride (8 mL), cooled to $0\text{ }^{\circ}\text{C}$, and treated with trifluoroacetic acid (8 mL). The reaction mixture was warmed to $23\text{ }^{\circ}\text{C}$ for 1 h, concentrated in vacuo and vacuum pumped dry. The crude oil was diluted into diethyl ether (5 mL) and methanol (11 mL), treated at $23\text{ }^{\circ}\text{C}$ with trimethylsilyl diazomethane (9 mL, 18 mmol, 2 M hexanes), maintained 5


min, quenched with dilute acetic acid in diethyl ether, the quench monitored by a positive TLC bromocresol green stain for excess HOAc, and the reaction mixture concentrated in vacuo. The crude product was purified by preparative centrifugal thin layer chromatography (Chromatotron, 4mm SiO₂, 0% to 20% ethyl acetate-hexane gradient elution) to provide the product as a (3:2) mixture of double bond isomers which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 339 (M⁺+1)).

EXAMPLE 77



EXAMPLE 76 (150 mg, 0.44 mmol) was treated with Et₂AlCN in toluene (13 mL, 13.3 mmol, 1M toluene) at room temperature. The reaction mixture was aged at 23 °C for 72 h, cooled to -78 °C, and slowly quenched with methanol resulting in an extremely exothermic reaction. The reaction mixture was then filtered over celite, washed excessively with (1:1) MeOH-acetonitrile, and concentrated in vacuo. The crude product was purified by preparative centrifugal thin layer chromatography (Chromatotron, 2mm SiO₂, 20% to 70% ethyl acetate-hexane gradient elution) to provide the product as a single diastereomer which was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 366 (M⁺+1)).


EXAMPLE 78



EXAMPLE 77 (20 mg, 0.055 mmol) was dissolved in THF (2 mL), treated with lithium aluminum hydride (21 mg, 0.55 mmol), and the reaction mixture stirred at 23 °C for 3 h. The mixture was then quenched with a saturated solution of Rochelle's salt, solid NaCl added to aid the extraction, and excessively partitioned with methylene chloride. The organic phase was then dried over anhydrous


sodium sulfate, and concentrated in vacuo to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 342 (M^++1)), and used directly in the next reaction to generate **EXAMPLE 79**.

5

EXAMPLE 79

EXAMPLE 78 (9 mg, 0.026 mmol) was dissolved in methylene chloride (2 mL), treated with pyridine (0.006 mL, 0.079 mmol), followed by ethanesulfonyl chloride (0.004 mL, 0.039 mmol), and the reaction mixture stirred at 23 °C for 1 h. The mixture was then either partitioned between $\text{NaHCO}_3(\text{aq})$ and CH_2Cl_2 , and used crude in the following reaction, or purified by loading the reaction mixture directly onto preparative thin layer chromatography (1500 micron SiO_2 , 20X20 cm, 50% EtOAc-hexane) to provide the product which was characterized by ^1H NMR, HPLC and mass spectrometry (m/z : 434 (M^++1)).

15


EXAMPLE 80

EXAMPLE 79 (10 mg, 0.023 mmol) was dissolved in benzene (1 mL), treated with recrystallized triphenylphosphine (7 mg, 0.025 mmol), followed by DIAD (0.005 mL, 0.025 mmol), and the reaction mixture stirred at 23 °C for 1 h. The mixture was then concentrated in vacuo and purified by preparative reversed phase HPLC (C18 SiO_2 , 0-100% acetonitrile gradient in water with 0.1% TFA eluent), followed

20

COMPOUND A (500 mg, 1.69 mmol) was dissolved in 17 mL of anhydrous tetrahydrofuran in an oven-dried vessel under argon atmosphere. Then in a separate oven-dried vessel of *t*-BuOAc (5.06 mmol, 700 μ L) was first cooled to -78°C and then diluted with lithium hexamethyldisilazane (1M in THF, 5.91 mmol, 6.0 mL) under argon atmosphere. The resulting reaction mixture was allowed to stir for 5 minutes. The solution of **COMPOUND A** was then added dropwise to the lithium enolate solution and allowed to stir for 30 minutes. The reaction mixture was quenched at -78°C with 20 mL of H_2O , extracted with ethyl acetate (3 x 20 mL), and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction mixture was purified by flash chromatography (SiO_2 , EtOAc/hexanes) to give the desired product as an orange viscous oil. The product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 413 ($M^+ + 1$)).

EXAMPLE 85




15

EXAMPLE 84 (600 mg, 1.46 mmol) was dissolved in 11 mL of anhydrous methylene chloride under argon atmosphere and cooled to 0°C . Then an equi-volume of trifluoroacetic acid (11 mL) was added dropwise, and the resulting reaction mixture was allowed to slowly warm to 23°C over 2 h. The reaction mixture was evaporated under reduced pressure, and the crude acid product was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z 357 ($M^+ + 1$)). This intermediate (518 mg, 1.46 mmol) was dissolved in 7 mL of anhydrous methylene chloride under argon atmosphere. Then triethyl amine (4.37 mmol, 0.630 mL) was added followed by diphenylphosphoryl azide (2.18 mmol, 0.462 mL). The resulting reaction mixture was allowed to stir over the duration of 3 days and, then was evaporated under reduced pressure. The crude reaction mixture was purified by flash chromatography (SiO_2 , EtOAc/hexanes) to give the desired product which was characterized by ^1H NMR, HPLC and mass spectroscopy (m/z : 354 ($M^+ + 1$)).

25


EXAMPLE 86



EXAMPLE 85 (50 mg, 0.14 mmol) was dissolved in 0.70 mL of anhydrous DMF under an argon atmosphere, and benzyl bromide (0.57 mmol, 0.067 mL) was added followed by sodium hydride (60 % in mineral oil, 0.28 mmol, 11 mg). The resulting reaction mixture was allowed to stir for 45 minutes. The reaction was quenched with 1 mL of H₂O, extracted with ethyl acetate (3 x 2 mL) and then the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction mixture was purified by flash chromatography (SiO₂, EtOAc/hexanes) to give the desired product which was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 444 (M⁺ + 1)).

EXAMPLES 87-92


The following compounds were prepared under conditions similar to those described in the examples above and illustrated in Scheme 15. The following examples were characterized by ¹H NMR, HPLC and mass spectrometry.



EXAMPLE	R Group	MS (m/z)
---------	---------	----------


		(M ⁺ +1)
87	methyl	368
88	allyl	394
89	isopropyl	396
90	2-methoxyethyl	412
91	CH ₂ CO ₂ Et	440
92	2-(1,3-dioxan)ethyl	468

EXAMPLE 93



- 5 **EXAMPLE 85** (50 mg, 0.14 mmol) was dissolved in 0.70 mL of anhydrous tetrahydrofuran under argon atmosphere. Then triethyl amine (0.57 mmol, 0.082 mL) was added followed by acetic anhydride (0.28 mmol, 0.027 mL). Next, the reaction mixture was treated with a catalytic amount of DMAP and allowed to stir for 12 h. The reaction mixture was quenched with 1 mL of H₂O, extracted with ethyl acetate (3 x 2 mL) and then the resulting organic layers were dried over sodium sulfate and evaporated under reduced
- 10 pressure. The crude reaction product was purified by flash chromatography (SiO₂, EtOAc/hexanes) to give the desired product which was characterized by ¹H NMR, HPLC and mass spectroscopy (m/z: 396 (M⁺ +1)).


COMPOUND I



15

4-Iodobenzoic acid (100 mg, 0.40 mmol) was dissolved in methanol. Then 4.0 equiv. of trimethylsilyl diazomethane (2.0 M in hexanes, 1.61 mmol, 0.800 mL) was slowly added until a yellow color remained, and the reaction mixture was allowed to stir for 1h. The reaction mixture was quenched with HOAc and evaporated under reduced pressure and the resulting oil was partitioned between H₂O and CH₂Cl₂. The aqueous layer was then extracted with methylene chloride (3 x 2 mL) and the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The product was characterized by ¹H NMR.

EXAMPLE 94




10

EXAMPLE 85 (50 mg, 0.14 mmol) was tared into a sealed pressure tube and 1 mol % of copper(I) iodide (0.014 mmol, 3 mg) and potassium phosphate (0.283 mmol, 60 mg) were added. The reactants of the tube were then diluted with 0.50 mL of anhydrous dioxane under an argon atmosphere, and *trans* 1,2-diaminocyclohexane (0.0014 mmol, 0.170 mL) was added followed by **COMPOUND I** (0.14 mmol, 37 mg). The reaction mixture was heated to 110°C and allowed to stir for 12 h before it was filtered over SiO₂, washed with EtOAc (5 mL) and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, EtOAc/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 488 (M⁺+1)).

20

EXAMPLE 95




EXAMPLE 94 (20 mg, 0.041 mmol) was dissolved in 0.410 mL of a mixture of H₂O:THF:MeOH
 5 (1:3:1). Then LiOH (1 M in H₂O, 0.16 mmol, 0.16 mL) was added, and the reaction mixture was
 allowed to stir for 12 h. The reaction mixture was then neutralized with 1 N HCl (0.16 mL) and followed
 by the addition of 0.30 mL of chloroform. The solution was then dried over sodium sulfate and
 evaporated under reduced pressure. The crude reaction product was purified by flash chromatography
 (SiO₂, EtOAc/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 474 (M⁺+1)).
 10

EXAMPLES 96-97

The following examples were prepared under conditions similar to those described in the example above
 and illustrated in Scheme 15. The following examples were characterized by ¹H NMR, HPLC and mass
 spectroscopy.


15



EXAMPLE	Ar-Group	MS (m/z) (M ⁺ +1)

96	phenyl	430
97	3-carboxyphenyl	474


EXAMPLE 98



5 **EXAMPLE 91** (59 mg, 0.13 mmol) was dissolved in 1.3 mL of a mixture of H₂O:THF:MeOH (1:3:1). Then LiOH (1 M, 0.54 mmol, 500 uL) was added, and the reaction mixture was allowed to stir for 12 h. The reaction mixture was then neutralized with 1 N HCl and followed by the addition of 1.5 mL of chloroform. The solution was then dried over sodium sulfate and evaporated under reduced pressure. The product was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 412 (M⁺+1)).

10

EXAMPLE 99




15 **EXAMPLE 98** (30 mg, 0.073 mmol) was dissolved in 0.70 mL of anhydrous methylene chloride under an argon atmosphere and *o*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate

(0.15 mmol, 56 mg) was added. Then aniline (0.73 mmol, 0.067 mL) was added followed by diisopropylethyl amine (1.09 mmol, 0.191 mL). The resulting reaction mixture was allowed to stir for 4 h at 23 °C. The reaction mixture was quenched with 1 mL of aqueous NaHCO₃, extracted with methylene chloride (3 x 2 mL) and then the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, acetone/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 487 (M⁺+1)).

10


EXAMPLE 100



15 **EXAMPLE 92** (12 mg, 0.026 mmol) was dissolved in 0.80 mL of tetrahydrofuran. Then 2N aqueous HCl (0.39 mmol, 193 uL) was added, and the reaction was heated to 85 °C and allowed to stir for 12 h. The reaction was quenched with 1 mL of H₂O, extracted with diethyl ether (3 x 2 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, acetone/hexanes) and characterized by ¹H NMR, HPLC and


20 mass spectrometry (m/z: 410 (M⁺+1)).

EXAMPLE 101



EXAMPLE 100 (10 mg, 0.024 mmol) was dissolved in 0.70 mL of anhydrous methylene chloride under argon atmosphere and $\text{NaBH}(\text{OAc})_3$ (0.049 mmol, 10 mg) was added. Then diisopropylethyl amine (0.073 mmol, 0.013 mL) was added followed by dimethylamine (0.037 mmol, 0.018 mL, 2 M THF). The resulting reaction mixture was allowed to stir for 12 h at 23 °C, quenched with 1 mL of aqueous NaHCO_3 , extracted with methylene chloride (3 x 2 mL), and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO_2 , acetone/hexanes) and characterized by ^1H NMR, HPLC and mass spectrometry (m/z: 439 ($\text{M}^+ + 1$)).

EXAMPLE 102



15


EXAMPLE 100 (10 mg, 0.024 mmol) was dissolved in 0.122 mL of anhydrous toluene under argon atmosphere and cooled to -78°C. Then DIBAL-H (0.049 mmol, 0.050 mL, 1 M toluene) was added, and the reaction mixture was stirred for 30 min at -78 °C. The reaction mixture was quenched with 0.500 mL

of Rochelle's salt, extracted with methylene chloride (3 x 1 mL), and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, acetone/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 412 (M⁺+1)).

5


10

EXAMPLE 103



15 **EXAMPLE 100** (10 mg, 0.024 mmol) was diluted in 0.350 mL of *t*-BuOH and 2-methyl-2-butene (0.61 mmol, 0.061 mL) was added. The reaction mixture was allowed to stir for 5 min at 23 °C, and then a solution of sodium chlorite (0.073 mmol, 7 mg) and mono-basic sodium phosphate (0.061 mmol, 10 mg) in 0.140 mL of H₂O was added. The reaction mixture was allowed to stir for 3 h at 23 °C, and then
20 quenched with 1 mL of aqueous NH₄Cl, extracted with methylene chloride (3 x 1 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, EtOAc/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 426 (M⁺+1)).


EXAMPLE 104



5 **EXAMPLE 103** (8 mg, 0.019 mmol) was dissolved in 0.250 mL of anhydrous methylene chloride under an argon atmosphere and cooled to 0°C. Then cyanamide (0.028 mmol, 1.2 mg) was added followed by diisopropylethyl amine (0.056 mmol, 0.010 mL), and EDCI (0.021 mmol, 4 mg). The reaction mixture was allowed to slowly warm to 23 °C over 12 h, then quenched with 0.500 mL of aqueous NH₄Cl, extracted with methylene chloride (3 x 0.500 mL), and then the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash
10 chromatography (SiO₂, acetone/hexanes) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 450 (M⁺+1)).


EXAMPLES 105 AND 106

15 **EXAMPLE 103** (15 mg, 0.035 mmol) was dissolved in 0.70 mL anhydrous chloroform which was first filtered through basic alumina under an argon atmosphere. A molar equivalent of methanesulfonamide or benzenesulfonamide was added. Then diisopropylethyl amine (0.35 mmol, 0.061 mL) was added followed by PyBOP (0.18 mmol, 92 mg) and a catalytic amount of DMAP. The resulting reaction mixture was allowed to stir at 23 °C for 5 h. The reaction mixture was quenched with 1 mL of aqueous
20 NaHCO₃, extracted with methylene chloride (3 x 1 mL) and then the resulting organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by flash chromatography (SiO₂, acetone/hexanes). The examples made through this procedure are outlined below and were characterized by ¹H NMR, HPLC and mass spectroscopy.




EX.	R-Group	MS (m/z) M ⁺ +1
105	methyl	503
106	phenyl	565

EXAMPLES 107 AND 108




EXAMPLE 107



EXAMPLE 108


In 6 mL of H₂O was dissolved 4.0 equiv of potassium cyanide (5.4 mmol, 356 mg) and 10 equiv of ammonium carbonate (13.5 mmol, 1.3 g). To this was added **COMPOUND A** (400 mg, 1.35 mmol) in 6 mL of ethanol. The reaction mixture was degassed with argon and heated to 125 °C for 48 h. The reaction mixture was then cooled to 23 °C, quenched with 50 mL of H₂O, extracted with methylene chloride (3 x 50 mL) and the organic layers were dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by column chromatography (SiO₂, MeOH/CH₂Cl₂) to give the separated hydantoin isomers as white solids which were each characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 367 (M⁺+1)).

EXAMPLE 109



5 **EXAMPLE 108** (20 mg, 0.056 mmol) was dissolved in 0.5 mL of acetone and 0.5 mL of ethanol under argon atmosphere, and potassium carbonate (0.066 mmol, 9 mg) was added. After 5 min, methyl iodide (0.083 mmol, 0.006 mL) was added, and the reaction mixture was warmed to 60 °C for 2 h before cooling to room temperature. The reaction mixture was then quenched by the addition of 25 mL of saturated aqueous NH₄Cl, extracted with methylene chloride (3 x 20 mL), and the organic layers were
10 dried over sodium sulfate and evaporated under reduced pressure. The crude reaction product was purified by column chromatography (SiO₂, methanol/CH₂Cl₂) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 381 (M⁺+1)).


EXAMPLE 110



15


EXAMPLE 110 was prepared from **EXAMPLE 108** according to the above procedure described in **EXAMPLE 109**. The product was characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 457 (M⁺+1)).

EXAMPLE 111



5 **EXAMPLE 110** (14 mg, 0.031 mmol) was dissolved in 0.5 mL DMF under argon atmosphere and cooled to 0 °C. To this was added sodium hydride [60% in mineral oil] (0.093 mmol, 4 mg) and methyl iodide (0.155 mmol, 0.011 mL), and the reaction mixture was allowed to warm to 23 °C over 5 h. The reaction mixture was then quenched by the addition of 20 mL of saturated aqueous NH₄Cl, extracted with methylene chloride (3 x 20 mL) and the organic layers were dried over sodium sulfate and
10 evaporated under reduced pressure. The crude reaction product was purified by column chromatography (SiO₂, methanol/CH₂Cl₂) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 471 (M⁺+1)).

EXAMPLE 112




15

EXAMPLE 107 (10 mg, 0.027 mmol) was dissolved in 0.5 mL of dioxane under an argon atmosphere and P₂S₅ (0.082 mmol, 18 mg) was added and the reaction mixture was heated to 110 °C for 5 h before it was cooled to room temperature, and then evaporated under reduced pressure. The crude reaction

product was purified by column chromatography (SiO₂,methanol/CH₂Cl₂) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 383 (M⁺+1)).

EXAMPLE 113




5

EXAMPLE 112 (5 mg, 0.013 mmol) was dissolved in 0.5 mL of ethanol and catalytic Raney nickel was added, and the reaction mixture was heated to 65 °C for 1 h before it was cooled to 23 °C. The reaction mixture was then filtered through celite, washed with ethyl acetate (10 mL) and evaporated under reduced pressure. The crude reaction product was purified by column chromatography (SiO₂,methanol/CH₂Cl₂) and characterized by ¹H NMR, HPLC and mass spectrometry (m/z: 353 (M⁺+1)).



15

EXAMPLES 114-136


The following examples were prepared under conditions similar to those described in the examples above and illustrated in Schemes 19-21. The following examples were characterized by ¹H NMR, HPLC, and mass spectroscopy.




20

EX.	W	X	Y	Z	MS (m/z) (M ⁺ +1)
114	C(O)	NCH ₃	C(O)	NH	381
115	NCH ₂ Ph	C(O)	NCH ₃	C(O)	471
116	NCH ₃	C(O)	NCH ₃	C(O)	395
117	NCH ₂ CH=CH ₂	C(O)	NCH ₃	C(O)	421
118	C(O)	NCH ₃	C(O)	NCH ₂ Ph	471
119	C(O)	NCH ₃	C(O)	NCH ₃	395
120	C(O)	NCH ₃	C(O)	NCH ₂ CH=CH ₂	421
121	C(O)	NCH ₃	C(O)	NH	381
122	N(CH ₂) ₂ CO ₂ H	C(O)	NCH ₂ Ph	C(O)	529
123	NH	C(O)	N(CH ₂) ₂ CO ₂ H	C(O)	439
124	NH	C(O)	N(CH ₂) ₂ 	C(O)	481
125	C(O)	NCH ₃	C(O)	N(CH ₂) ₂ CO ₂ H	453
126	C(O)	NCH ₃	C(O)	N(CH ₂) ₂ 	495
127	NCH ₂ CH=CH ₂	C(O)	NCH ₂ CH=CH ₂	C(O)	447
128	NCH ₂ Ph	C(O)	NCH ₂ Ph	C(O)	547
129	NH	C(S)	NCH ₂ Ph	C(O)	473

130	NH	C(S)	NH	C(O)	383
131	NH	C(S)	NCH ₂ CH=CH ₂	C(O)	423
132	NH	C(S)	NCH ₃	C(O)	397
133	NH	CH ₂	NCH ₂ Ph	C(O)	443
134	NH	CH ₂	NH	C(O)	353
135	C(O)	NCH ₃	CH ₂	NCH ₃	381
136	NH	CH ₂	NCH ₃	C(O)	367

COMPOUND C

5


Step 1:

10 Triton B (benzyltrimethylammonium hydroxide (29.8 g, 74.6 mL of a 40 wt. % solution in MeOH, 178 mmol) was added to a solution of 1,3-cyclohexanedione in water (90 mL) followed by benzyl bromide (36.6 g, 25.5 mL, 214 mmol) at room temperature. The two phase mixture was stirred vigorously

overnight after which time the product crystallized and was collected by filtration and washed with CH_2Cl_2 (50 mL) to give **COMPOUND D** (13.38 g). The filtrate was concentrated in vacuo and purified by flash chromatography (110 g Si, 50 mL/min, isocratic at 100% hexane for 5 min, gradient to 50% EtOAc in hexanes over 10 min, gradient to 80% EtOAc in hexanes over 30 min) to give further **COMPOUND D** (3.79 g, total yield 48%) as a colorless solid. LCMS (ES+) 203 (M+H)⁺; ¹H NMR (DMSO-d₆, 500 MHz) δ 7.16 (4H, m), 7.07 (1H, m), 3.57 (3H, br s), 2.35 (4H, br s), 1.83 (2H, quintet, J 6.2 Hz).

Step 2:

10




15

Methyl vinyl ketone (2.48 g, 2.94 mL, 35.3 mmol) was added to a solution of **COMPOUND D** (6.69 g, 23.6 mmol) in MeOH (20 mL) followed by Triton B (0.394 g, 0.985 mL of a 40 wt. % solution in MeOH, 2.36 mmol). The reaction was stirred at 60 °C for 6 h then overnight at room temperature after which time the product crystallized. The product was collected by filtration and washed with MeOH to afford **COMPOUND E** (3.97 g, 44%) as colorless solid. LCMS (ES+) 272 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.19 (3H, m), 6.98 (2H, m), 3.05 (2H, s), 2.47 (2H, ddd, J 17.1, 7.8, 4.7 Hz), 2.27 (2H, t, J 7.3 Hz), 2.15 (2H, ddd, J 17.2, 8.8, 4.9 Hz), 2.12 (2H, t, J 7.3 Hz), 1.71 (1H, m), 1.34 (1H, m).


20

Step 3:



A solution of **COMPOUND E** (5.47 g, 20.1 mmol) was heated at reflux in benzene (100 mL) with a Dean Stark apparatus attached. Water was azeotroped and the reaction was removed from reflux before adding pyrrolidine (1.43 g, 1.67 mL, 20.1 mmol). The reaction was heated at reflux for 2 h after which time water was azeotroped from the reaction. The reaction was allowed to cool and Et₂O (100 mL) was added. The mixture was washed with 1N HCl (100 mL) followed by water (100 mL). The aqueous layers were back extracted with Et₂O (2 x 100 mL) and the combined organic layers were washed with brine (100 mL) dried (MgSO₄) and concentrated *in vacuo* to afford recovered starting material (0.792 g). The aqueous layer was extracted with EtOAc (3 x 100 mL) and the combined extracts were dried (MgSO₄) then concentrated *in vacuo* to afford **COMPOUND F** (0.683 g) as a colorless solid. The aqueous layer was further extracted with CH₂Cl₂ (4 x 200 mL) and the combined extracts were dried (MgSO₄) then concentrated *in vacuo* to afford more of the desired **COMPOUND F** as the pyrrolidine imminium chloride salt at the 1-position (4.797 g). A solution of this compound in AcOH (4 mL), MeOH (50 mL) and water (10 mL) containing NaOAc (4.0 g) was heated at reflux overnight. The solvents were removed *in vacuo*, the residue was treated with 1N HCl (100 mL) and the product was extracted with CH₂Cl₂ (3 x 200 mL). The combined organic extracts were washed with dilute aqueous Na₂CO₃ and water, dried (Na₂SO₄) and concentrated *in vacuo* to afford further **COMPOUND F** (2.348 g, total yield 59%) as a solid. LCMS (ES+) 255 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.28 (3H, m), 7.05 (2H, m), 5.98 (1H, br s), 3.22 (1H, d, *J* 13.6 Hz), 3.16 (1H, d, *J* 13.6 Hz), 2.72 (1H, m), 2.66 (1H, m), 2.60 (1H, m), 2.54 (1H, m), 2.40 (1H, m), 2.31 (1H, m), 2.16 (1H, m), 2.11(1H, m), 2.02 (1H, dt, *J* 14.2, 5.7 Hz), 1.72 (1H, m).

Step 4:



25


p-Toluenesulfonic acid monohydrate (0.749 g, 3.93 mmol) was added quickly in one portion to a solution of **COMPOUND F** (1.00 g, 3.93 mmol) in ethylene glycol (19.6 mL) containing 4Å molecular sieves. The resulting solution was stirred at room temperature for 23 min, after which time it was poured into a mixture of ice and saturated NaHCO₃ (100 mL). The solution was extracted with EtOAc (1 x 200 mL, 2 x 100 mL), the combined organic layers were washed with brine (100 mL) and the brine layer was back

30

extracted with EtOAc (100 mL). The combined organic extracts were dried (MgSO_4) and concentrated *in vacuo* to give a crude oil (~1.3 g). This was purified by flash chromatography (110 g Si, 70 mL/min, gradient from 0 to 40% EtOAc in hexanes over 40 min) followed by further flash chromatography on the fractions containing the desired product (35 g Si, 40 mL/min, 20% EtOAc in hexanes to give

5 **COMPOUND G** (275.0 mg, 23%) as a colorless oil. LCMS (ES+) 299 ($\text{M}+\text{H}$)⁺; ¹H NMR (CDCl_3 , 500 MHz) δ 7.19 (3H, m), 7.12 (2H, m), 5.94 (1H, d, *J* 1.5 Hz), 4.00 (4H, m), 3.33 (1H, d, *J* 13.5 Hz), 3.03 (1H, d, *J* 13.5 Hz), 2.77 (1H, tdd, *J* 13.8, 6.3, 1.7 Hz), 2.38 (1H, m), 2.26 (1H, tdd, *J* 13.5, 6.1, 1.2 Hz), 2.06-1.67 (6H, m), 1.04 (1H, ddd, *J* 16.8, 13.3, 6.5 Hz).

10 Step 5:




COMPOUND G (275 mg, 0.923 mmol) was dissolved in benzene (20 mL) and ~ 5 mL was distilled off azeotropically to dry the solvent. The solution was cooled to ~10 °C and ethyl formate (288.1 mg, 314 μL , 3.69 mmol) was added followed by NaH (147 mg of a 60% dispersion in oil 3.69 mmol). After 3 min MeOH (20 μL) was added and the reaction mixture became brown. The reaction was stirred at room temperature for 3 h, then cooled to 0 °C and water (50 mL) was added slowly. Et₂O (50 mL) was added and the organic layer was washed with water (3 x 50 mL). The combined aqueous phases were washed

15


20 with Et₂O (100 mL) and acidified to pH 5.5-6 with saturated KH_2PO_4 (~20 mL) followed by addition of 3N HCl (18 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL) and the combined organic extracts were dried (Na_2SO_4) and concentrated *in vacuo* to afford **COMPOUND H** (222.1 mg, 74%) as a brown oil. This was used in the next step without any further purification. LCMS (ES+) 327 ($\text{M}+\text{H}$)⁺.

25 Step 6:




p-Fluorophenyl hydrazine hydrochloride (166.2 mg, 0.681 mmol) and NaOAc (139.1 mg, 1.02 mmol) were successively added to a solution of **COMPOUND H** (222.1 mg, 0.681 mmol) in acetic acid (10 mL) at room temperature under N₂. The mixture was stirred at room temperature overnight and then added slowly to a 10% saturated NaHCO₃ solution (100 mL). Saturated NaHCO₃ was added dropwise until effervescence ceased. The aqueous mixture was extracted with EtOAc (3 x 100 mL) and the combined organic extracts were washed with brine (100 mL), dried (MgSO₄) and concentrated *in vacuo* to afford the crude product. This was purified by flash chromatography (35 g Si, 40 mL/min, isocratic at 100% hexanes for 5 min, gradient to 20% EtOAc over 25 min, isocratic at 20% EtOAc in hexanes for 10 min) to give **EXAMPLE 139** (162.3 mg, 57%) as a colorless oil. LCMS (ES+) 417 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.10 (6H, m), 6.99 (4H, m), 6.14 (1H, d, *J* 2.1 Hz), 4.07 (4H, m), 3.28 (1H, d, *J* 16.6 Hz), 3.10 (1H, d, *J* 13.2 Hz), 2.85 (1H, d, *J* 13.0 Hz), 2.80 (1H, d, *J* 16.5 Hz), 2.71 (1H, tdd, *J* 14.0, 5.6, 2.4 Hz), 2.35 (1H, br d, *J* 15.2 Hz), 1.97 (1H, td, *J* 13.5, 4.6 Hz), 1.86-1.67 (3H, m).

15


Step 7:

20 6N HCl (0.26 mL, 1.55 mmol) was added to a solution of **EXAMPLE 12** (161 mg, 0.387 mmol) in THF (10 mL) and the resulting solution was heated at reflux for 5 h. The reaction mixture was cooled and

added slowly to 10% saturated Na_2CO_3 (100 mL). The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organic phases were dried (MgSO_4) and concentrated *in vacuo* to afford the crude product (172.6 mg). This was purified by flash chromatography (10 g Si, 25 mL/min, isocratic at 100% hexanes for 4 min, gradient to 20% EtOAc in hexanes over 30 min, isocratic at 20% EtOAc in
 5 hexanes for 10 min) to give ketone C (128.2 mg, 89%) as a colorless oil. Ketone C was resolved into its two enantiomers by chiral HPLC (OD, 20 x 250 mm, isocratic at 3% EtOH in heptane) to give **(R)-COMPOUND C** and **(S)-COMPOUND C** (67.1 and 61.6 mg respectively) in order of elution. LCMS (ES+) 373 (M+H)⁺; ¹H NMR (CDCl_3 , 500 MHz) δ 7.45 (3H, m), 7.20 (5H, m), 6.98 (2H, m), 6.38 (1H, br d, *J* 1.9 Hz), 3.03 (1H, d, *J* 13.1 Hz), 3.02 (1H, d, *J* 16.6 Hz), 2.85 (1H, d, *J* 13.3 Hz), 2.71 (1H, d, *J*
 10 16.6 Hz), 2.61 (1H, m), 2.55 (1H, dd, *J* 12.7, 5.9 Hz), 2.51 (1H, m), 2.37 (1H, m), 2.00 (1H, m), 1.64 (1H, qt, *J* 13.1, 4.3 Hz).


COMPOUND I

15

Step 1:


20

A suspension of CrO_3 (294 mg, 2.94 mmol) in dry CH_2Cl_2 (2 mL) was stirred vigorously for a few minutes at $-20\text{ }^\circ\text{C}$ under nitrogen and 3,5-dimethylpyrazole (424 mg, 4.41 mmol) was added quickly in one portion. The mixture was stirred vigorously for 15 min. A solution of **EXAMPLE 138** (50 mg, 0.147 mmol) in dry CH_2Cl_2 (2 mL) was added by cannula. The mixture was stirred vigorously for 2 h at
 25 $-20\text{ }^\circ\text{C}$. The reaction was warmed to $0\text{ }^\circ\text{C}$ and 6N NaOH (1 mL) was added and the mixture was stirred




A solution of crude **EXAMPLE 141** (28.2 mg) in 6N aqueous HCl (300 μL) and THF (7 mL) was heated at 50 $^{\circ}\text{C}$ for 6 h. The reaction was diluted with EtOAc (25 mL) and 10% Na_2CO_3 (25 mL). The aqueous layer was extracted with EtOAc (2 x 25 mL) and the combined organic extracts were dried (MgSO_4) and concentrated *in vacuo* to afford the crude product. This was purified by flash chromatography (10 g Si, 25 mL/min, gradient from 0 to 30% EtOAc in hexanes over 60 min) to give ketone **I** (13.1 mg). LCMS (ES+) 309 ($\text{M}+\text{H}$) $^+$; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 7.52 (1H, s), 7.48 (2H, d, J 8.9, 4.7 Hz), 7.18 (2H, J 8.4 Hz), 6.18 (1H, s), 5.80 (1H, br s), 3.45 (1H, br d, J 21.5 Hz), 3.05 (1H, d, J 16.3 Hz), 3.02 (1H, ddd, J 21.5, 4.9, 1.4 Hz), 2.81 (1H, d, J 16.6 Hz), 1.93 (3H, s), 1.29 (3H, s).

COMPOUND J




15

Step 1:




A suspension of CrO₃ (306 mg, 3.06 mmol) in dry CH₂Cl₂ (2 mL) was stirred vigorously for 15 min at -20 °C under nitrogen and 3,5-dimethylpyrazole (442 mg, 4.60 mmol) was added quickly in one portion. The mixture was stirred vigorously for 1 h. A solution of **EXAMPLE 142** (50 mg, 0.153 mmol) in dry CH₂Cl₂ (2 mL) was added by cannula. The mixture was stirred vigorously for 2 h at -20 °C. The reaction was warmed to 0 °C and 6N NaOH (1 mL) was added and the mixture was stirred at 0 °C for 1 h. The mixture was diluted with CH₂Cl₂ (20 mL) then washed with water (20 mL), 10% aqueous HCl (20 mL), water (20 mL), and brine (20 mL). The organic layer was dried (MgSO₄) and concentrated *in vacuo* to afford the crude product (191 mg). This was purified by flash chromatography (10 g Si, 25 mL/min, gradient from 0 to 30% EtOAc in hexanes over 60 min) to give **EXAMPLE 143** (29.8 mg, 57%) as a light yellow oil. LCMS (ES+) 341 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.51 (1H, s), 7.43 (2H, d, *J* 8.9, 4.7 Hz), 7.16 (2H, *J* 8.4 Hz), 7.13 (1H, s), 3.99 (4H, m), 3.36 (1H, d, *J* 16.0 Hz), 2.90 (1H, d, *J* 18.1 Hz), 2.62 (1H, d, *J* 18.1 Hz), 2.55 (1H, d, *J* 16.0 Hz), 1.34 (3H, s).

15 Step 2:



A suspension of CeCl₃ (2.55 g, 10.36 mmol) in dry THF (25 mL) was stirred vigorously for 2 h at room temperature under nitrogen until cloudy. The mixture was cooled to -78 °C and MeLi (4.80 mL of a 1.6 M solution in Et₂O, 8.63 mmol) was added. The dark orange mixture was stirred at -78 °C for 1 h. A solution of **EXAMPLE 143** (293.4 mg, 0.863 mmol) in dry THF (10 mL) was added by cannula and the reaction was stirred at -78 °C for 6 h then at room temperature overnight. The reaction was quenched by the addition of saturated NH₄Cl (2 mL) and partitioned between water (100 mL) and EtOAc (100 mL). The aqueous layer was extracted with EtOAc (2 x 100 mL) and the combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to afford the crude product (370 mg). This was purified by flash chromatography (35 g Si, 40 mL/min, 0 to 30% EtOAc in hexanes over 60 min) to give **EXAMPLE 144** (73.9 mg, 25%,) as a pale yellow solid. LCMS (ES+) 339 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.47 (2H, d, *J* 8.9, 4.7 Hz), 7.44 (1H, s), 7.14 (2H, *J* 8.9 Hz), 6.19 (1H, s), 5.79 (1H, s), 3.99 (4H, m), 3.08 (1H, d, *J* 15.4 Hz), 2.43 (1H, d, *J* 15.4 Hz), 1.85 (3H, br s), 1.09 (3H, s).


Step 3:

5


A solution of **EXAMPLE 144** (73.9 mg, 0.219 mmol) in 6N HCl (1 mL) and THF (20 mL) was heated to 55 °C for 4 h. The reaction mixture was diluted with EtOAc (40 mL) and saturated Na₂CO₃ (40 mL). The aqueous layer was extracted with EtOAc (2 x 25 mL). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give the crude product. This was purified by flash

10 chromatography (10 g Si, 25 mL/min, 0.5% MeOH in CHCl₃) to give ketone **J** (64.0 mg, 100%) as a pale yellow oil. LCMS (ES+) 295 (M+H)⁺; ¹H NMR (CDCl₃, 600 MHz) δ 7.56 (1H, s), 7.51 (2H, d, *J* 8.9, 4.8 Hz), 7.20 (2H, *J* 8.6 Hz), 6.48 (1H, s), 6.14 (1H, s), 2.85 (1H, d, *J* 15.9 Hz), 2.53 (1H, d, *J* 15.9 Hz), 2.22 (3H, br s), 1.18 (3H, s).

15


COMPOUND KStep 1:

20



2-Butyn-1-yl diethyl acetal (5 g, 35.2 mmol) and oxalic acid (316 mg, 3.53 mmol) were stirred as an emulsion in water (10 mL) at 75 °C for 5 h. The mixture was diluted with water (50 mL) and extracted with CH₂Cl₂ (3 x 100 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated *in vacuo* to afford the crude **COMPOUND L** as a colorless oil. This compound was used in the next step with no further purification. ¹H NMR (CDCl₃, 500 MHz) δ 9.11 (1H, s), 2.04 (3H, s).


Step 2:




COMPOUND L above was dissolved in THF (8 mL) and added by cannula to a stirred suspension of zinc (2.34 g, 0.0352 mol) and CuSO₄ in THF (2 mL) at room temperature under N₂, followed by dropwise addition of AcOH. The suspension was stirred at room temperature for 3 h. The mixture was filtered to remove the zinc and CuSO₄ and the solid residues were washed with Et₂O (3 x 100 mL). The filtrate was then neutralized with a solution of saturated K₂CO₃ (200 mL) and the organic layer was separated. The aqueous layer was extracted with Et₂O (3 x 100 mL). The combined organic layers were dried (MgSO₄) and concentrated *in vacuo* to afford the crude product (570.5 mg). This was purified by flash chromatography (35 g Si, 40 mL/min, gradient from 20 to 50% EtOAc in hexanes over 37 min) to give diol **K** (245.6 mg, 10%), as a pale yellow oil. A small sample of this was recrystallized from EtOAc/hexanes to give **COMPOUND H** (43.7 mg) as a pale yellow solid, m.p. 106-107 °C (lit. 116 °C). ¹H NMR (CDCl₃, 500 MHz) δ 4.38 (2H, s), 1.90 (6H, s).

COMPOUND M


25



Step 1:

- 5 A solution of di-*i*-propyl D-tartrate (25 g, 106 mmol), 2,3-dimethoxypropane (15.6 g, 18.4 mL, 149 mmol) and *p*-toluenesulfonic acid (81.2 mg, 0.426 mmol) in benzene (150 mL) was heated at reflux overnight. The reaction mixture was washed with saturated K_2CO_3 dried (MgSO_4) and concentrated *in vacuo* to afford **COMPOUND N** as a colorless oil in quantitative yield. Spectroscopic data agreed with that published in the literature.

10


Step 2:

- 15 A solution of DIBALH (38.6 mL of 1 M solution in hexanes, 38.6 mmol) was added to a stirred solution of **COMPOUND N** (5 g, 19.3 mmol) in dry toluene (60 mL) at -78°C under nitrogen. The mixture was stirred at -78°C for 3 h. A solution of sodio methyl diethylphosphonoacetate (obtained by adding at 0°C , methyl diethylphosphoacetate (10.1 g, 8.85 mL, 48.2 mmol) in dry DME (20 mL) to a suspension of NaH (2.05 g, 60% dispersion in oil, 51.5 mmol) in dry DME (20 mL) and stirring the mixture for 30 min
- 20 at room temperature) was added at -78°C . After 5 min the cooling bath was removed and the reaction mixture was allowed to warm to room temperature and was stirred overnight. Water (50 mL) was added and the mixture was poured into Et_2O (500 mL). The organic layer was washed with water (4 x 50 mL), dried (MgSO_4) and concentrated *in vacuo* to afford the crude product (7.17 g). This was purified by flash chromatography (110 g Si, 70 mL/min, 100% hexanes for 5 min, gradient to 10% EtOAc in hexanes
- 25 over 20 min, isocratic at 10% EtOAc in hexanes for 40 min) to give **COMPOUND O** (501.8 mg) as a

colorless oil. LCMS (ES+) 293 (M+Na)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 6.85 (2H, d, *J* 15.6 Hz), 6.15 (2H, d, *J* 15.6 Hz), 4.25 (2H, m), 3.75 (6H, s), 1.45 (6H, s).

Step 3:

5




DIBALH (3.1 mL of a 1M solution in hexanes, 3.09 mmol) was added dropwise to a stirred solution of **COMPOUND O** in dry CH₂Cl₂ at -78 °C under nitrogen. The reaction mixture was allowed to warm slowly to 0 °C over 4 h and was quenched by the addition of saturated NH₄Cl (8 mL). The resulting thick slurry was filtered through Celite. The residue was triturated repeatedly with EtOAc (3 x 50 mL) and filtered through Celite. The combined filtrates were dried (Na₂SO₄) and concentrated *in vacuo* to give the crude product (170.9 mg). This was purified by flash chromatography (10 g Si, 25 mL/min, gradient from 65 to 100% EtOAc in hexanes over 30 min, then isocratic at 100% EtOAc for 7 min) to give **COMPOUND P** (96.3 mg, 67%) as a colorless oil. ¹H NMR (CDCl₃, 500 MHz) δ 5.90 (2H, dt, *J* 15.5, 5.0 Hz), 5.64 (2H, br d, *J* 15.5 Hz), 4.09 (6H, m), 3.01 (2H, br s), 1.40 (6H, s).

10

15

Step 4:




20

CBr₄ (358 mg, 1.08 mmol) and Ph₃P (283 mg, 1.08 mmol) were added successively to a stirred solution of **COMPOUND P** (96.3 mg, 0.450 mmol) in dry CH₂Cl₂ (2 mL) at 0 °C. The reaction was stirred at 0 °C for 1 h. After evaporation of the solvent *in vacuo*, the residue was purified by flash chromatography (10 g Si, 25 mL/min, isocratic at 100% hexanes for 5 min, gradient to 10% EtOAc in hexanes over 20

25


min, then isocratic at 10% EtOAc in hexanes for 15 min) to give **COMPOUND Q** (132.9 mg, 87%) as a colorless oil. $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 5.98 (2H, dt, J 15.2, 7.5 Hz), 5.70 (2H, br dd, J 15.2, 5.3 Hz), 4.07 (2H, m), 3.92 (4H, d, J 7.5 Hz), 1.40 (6H, s).

5 Step 5:



LiAlH₄ (3.82 mL of a 1 M solution in Et₂O, 3.82 mmol) was added to a stirred solution of **COMPOUND Q** (298.3 mg, 0.877 mmol) in dry Et₂O (6 mL) under nitrogen and the reaction mixture was heated at reflux for 1 h. The reaction was cooled to 0 °C and saturated NH₄Cl (1 mL) was added to quench the reaction. The resulting slurry was filtered through Celite and the precipitate was washed with Et₂O. The filtrate was washed with brine (20 mL), dried (MgSO₄) and concentrated *in vacuo* to afford **COMPOUND R** (125.9 mg, 79%) as a colorless oil. $^1\text{H NMR}$ (CDCl_3 , 600 MHz) δ 5.75 (2H, dq, J 15.2, 6.5 Hz), 5.38 (2H, br d, J 15.2 Hz), 3.98 (2H, dd, J 5.3, 2.1 Hz), 1.68 (6H, dd, J 6.6, 1.7 Hz), 1.37 (6H, s).

Step 6:




20

A solution of **COMPOUND R** (115.9 mg, 0.637 mmol) in 1N HCl/THF (1:1, 30 mL) was stirred at room temperature for 3 h. The reaction mixture was diluted with CH₂Cl₂ (50 mL) and water (50 mL). The organic layer was separated and dried (Na₂SO₄) then concentrated *in vacuo* to give **COMPOUND M** (89.5 mg, 99%) as a colorless oil. $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 5.77 (2H, dq, J 15.4, 6.6 Hz), 5.47


25

(2H, br d, *J* 15.4 Hz), 3.91 (2H, d, *J* 6.0 Hz), 1.71 (6H, dd, *J* 6.6, 1.5 Hz).

COMPOUND S




5




10 $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (52.6 mg, 47 μL , 0.370 mmol) and 1,2-ethanedithiol (41.9 mg, 37 μL , 0.444 mmol) were added successively to a stirred solution of **COMPOUND N** in dry CH_2Cl_2 at room temperature under nitrogen. After 30 min the reaction was quenched with saturated NaHCO_3 (3 mL) and stirred for a further 30 min. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried (MgSO_4) and concentrated *in vacuo* to afford **COMPOUND R** (46.5 mg, 85%) as a colorless solid. $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ 6.98 (2H, dd, *J* 15.6, 4.2 Hz), 6.10 (2H, dd, *J* 15.6, 1.1 Hz), 4.80 (2H, br s), 4.33 (2H, t, *J* 1.8 Hz), 3.72 (6H, s).

15

COMPOUND T





20



This compound was prepared using a literature procedure (Sharpless, K. B., Amberg, W., Bennani, Y. L., Crispino, G. A., Hartung, G., Jeong, K. S., Kwong, H. L., Morikawa, K., Wang, Z. M., Xu, D., and Zhang, X. L. *J. Org. Chem.* **1992**, *57*, 2768-2771). $^1\text{H NMR}$ (CDCl_3 , 500MHz) δ 3.37-3.41 (2H, m), 2.28 (2H, bs), 1.58-1.66 (2H, m), 1.46-1.52 (2H, m), 1.01 (6H, t, J 7.5 Hz).


5

COMPOUND U


10

This compound was prepared using a literature procedure (Sharpless, K. B., Amberg, W., Bennani, Y. L., Crispino, G. A., Hartung, G., Jeong, K. S., Kwong, H. L., Morikawa, K., Wang, Z. M., Xu, D., and Zhang, X. L. *J. Org. Chem.* **1992**, *57*, 2768-2771). $^1\text{H NMR}$ (CDCl_3 , 500MHz) δ 3.40-3.70 (2H, m), 2.03 (2H, bs), 1.50-1.58 (4H, m), 1.38-1.48 (4H, m), 0.98 (6H, t, J 6.9 Hz).

15

COMPOUND V

5




10


This compound was prepared using a literature procedure (Sharpless, K. B., Amberg, W., Bennani, Y. L., Crispino, G. A., Hartung, G., Jeong, K. S., Kwong, H. L., Morikawa, K., Wang, Z. M., Xu, D., and Zhang, X. L. *J. Org. Chem.* **1992**, *57*, 2768-2771). ¹H NMR (CDCl₃, 500MHz) δ 3.42-3.60 (2H, m), 2.06 (2H, bs), 1.42-1.55 (6H, m), 1.35-1.41 (6H, m), 0.95 (6H, t, *J* 7.1 Hz).

EXAMPLES

15



EXAMPLE 145





A solution of **COMPOUND A** (25.1 mg, 0.0847 mmol) and 3-methoxy-1,2-propanediol (89.9 mg, 80.7 μL , 0.847 mmol) in benzene (25 mL) was heated at reflux with a Dean Stark apparatus attached and ~ 5 mL of solvent was distilled over to azeotrope water from the reaction. The reaction was removed from reflux and *p*-toluenesulfonic acid monohydrate (4.8 mg, 0.0245 mmol) was added. The reaction was heated at reflux for 5 h. The solution was cooled and diluted with EtOAc (20 mL). The mixture was washed with saturated NaHCO_3 (20 mL), water (20 mL) and brine (20 mL), dried (MgSO_4), then concentrated *in vacuo* to give the crude product. This was purified by flash chromatography (4 g Si, 10 mL/min, gradient from 0 to 20% EtOAc in hexanes over 40 min) to give **EXAMPLE 145** as a mixture of four diastereoisomers. The diastereoisomers were separated by chiral HPLC (AD, 20 x 250 mm, 9 mL/min, isocratic at 1.5% EtOH in heptane) to give four diastereoisomers (**EXAMPLES 146, 147, 148 and 149**, 6.3, 3.7, 5.3, 5.9 mg in order of elution, overall yield 65%) as colorless oils. Major diastereoisomer: LCMS (ES+) 385 ($\text{M}+\text{H}^+$); ^1H NMR (CDCl_3 , 500 MHz) δ 7.44 (2H, dd, *J* 8.9, 4.9 Hz), 7.42 (1H, s), 7.14 (2H, t, *J* 8.6 Hz), 6.17 (1H, br d, *J* 2.2 Hz), 4.36 (1H, br quintet, *J* 6.3 Hz), 4.13 (1H, t, *J* 7.4 Hz), 3.67 (1H, t, *J* 7.5 Hz), 3.60 (1H, dd, *J* 9.8, 5.5 Hz), 3.48 (1H, dd, *J* 9.8, 5.5 Hz), 3.37 (3H, s), 3.30 (1H, d, *J* 16.0 Hz), 2.47 (1H, d, *J* 15.8 Hz), 2.42 (1H, m), 2.27 (1H, br d, *J* 15.4 Hz), 1.85 (1H, m), 1.79 (1H, m), 1.70 (1H, m), 1.60 (1H, m), 1.19 (3H, s).

EXAMPLE 150







5






A solution of **COMPOUND C** (20.9 mg, 0.0562 mmol) and (3R,4R)-1,5-hexadien-3,4-diol (64.1 mg, 0.562 mmol) in benzene (25 mL) was heated at reflux with a Dean Stark apparatus attached and ~ 5 mL of solvent was distilled over to azeotrope water from the reaction. The reaction was removed from reflux and *p*-toluenesulfonic acid monohydrate (3.2 mg, 0.0169 mmol) was added. The reaction was heated at reflux overnight. The solution was cooled and diluted with EtOAc (20 mL). The mixture was washed with saturated NaHCO₃ (20 mL), water (20 mL) and brine (20 mL), dried (MgSO₄), then concentrated *in vacuo* to give the crude product. This was purified by flash chromatography (10 g Si, 25 mL/min, gradient from 0 to 20% EtOAc in hexanes over 40 min) to give **EXAMPLE 150** (11.9 mg, 45%) as a colorless oil. LCMS (ES+) 469 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.14-7.06 (6H, br m), 7.01-6.97 (4H, br m), 6.13 (1H, d, *J* 2.1 Hz), 5.94 (1H, ddd, *J* 17.2, 10.4, 6.7 Hz), 5.81 (1H, ddd, *J* 17.2, 10.4, 6.7 Hz), 5.45 (1H, d, *J* 17.2 Hz), 5.36 (1H, d, *J* 10.4 Hz), 5.34 (1H, d, *J* 17.2 Hz), 5.22 (1H, d, *J* 10.4 Hz), 4.29 (1H, t, *J* 7.6 Hz), 4.18 (1H, t, *J* 7.4 Hz), 3.25 (1H, d, *J* 16.3 Hz), 3.05 (1H, d, *J* 13.1 Hz), 2.89 (1H, d, *J* 13.1 Hz), 2.88 (1H, d, *J* 16.3 Hz), 2.71 (1H, m), 2.38 (1H, d, *J* 14.8 Hz), 2.08 (1H, m), 1.93 (1H, m), 1.86 (2H, m).





20





EXAMPLES





The following compounds are synthesized from either compound A, B, C, I, or J in racemic or
 5 enantiopure form and commercially available diols or dithiols, or diols whose syntheses are described
 above, using procedures analogous to that described for **EXAMPLE 145**:





Example	Molecular structure	LCMS (M+1) ⁺
151	 <p style="text-align: center;">racemic</p>	341
152	 <p style="text-align: center;">single diastereoisomer</p>	369
153	 <p style="text-align: center;">mixture of diastereoisomers</p>	369
154		369





<p>155</p>		<p>369</p>
<p>156</p>		<p>369</p>
<p>157</p>	 <p style="text-align: center;">mixture of diastereoisomers</p>	<p>397</p>
<p>158</p>	 <p style="text-align: center;">mixture of diastereoisomers</p>	<p>397</p>
<p>159</p>		<p>397</p>





<p>160</p>	 <p>mixture of diastereoisomers</p>	<p>425</p>
<p>161</p>	 <p>mixture of diastereoisomers</p>	<p>425</p>
<p>162</p>		<p>425</p>
<p>163</p>		<p>453</p>





<p>164</p>	 <p>mixture of diastereoisomers</p>	<p>481</p>
<p>165</p>	 <p>mixture of diastereoisomers</p>	<p>393</p>
<p>166</p>		<p>393</p>
<p>167</p>		<p>421</p>





<p>168</p>		<p>417</p>
<p>169</p>	<p>single diastereoisomer</p> 	<p>457</p>
<p>170</p>		<p>457</p>
<p>171</p>	 <p>mixture of diastereoisomers</p>	<p>397</p>






<p>172</p>	 <p>mixture of diastereoisomers</p>	<p>381</p>
<p>173</p>	 <p>mixture of diastereoisomers</p>	<p>381</p>
<p>174</p>	 <p>mixture of diastereoisomers</p>	<p>395</p>
<p>175</p>		<p>395</p>





<p>176</p>	 <p>mixture of diastereoisomers</p>	<p>443</p>
<p>177</p>	 <p>mixture of diastereoisomers</p>	<p>499</p>
<p>178</p>	 <p>mixture of diastereoisomers</p>	<p>505</p>
<p>179</p>	 <p>mixture of diastereoisomers</p>	<p>493</p>





<p>180</p>	 <p>mixture of diastereoisomers</p>	<p>493</p>
<p>181</p>	 <p>mixture of diastereoisomers</p>	<p>493</p>
<p>182</p>	 <p>mixture of diastereoisomers</p>	<p>561(m)</p>
<p>183</p>	 <p>mixture of diastereoisomers</p>	<p>561(m)</p>






<p>184</p>	 <p style="text-align: center;">mixture of diastereoisomers</p>	<p>429</p>
<p>185</p>	 <p style="text-align: center;">mixture of diastereoisomers</p>	<p>429</p>
<p>186</p>		<p>429</p>
<p>187</p>	 <p style="text-align: center;">mixture of diastereoisomers</p>	<p>581</p>






<p>188</p>	 <p>mixture of diastereoisomers</p>	<p>649(m)</p>
<p>189</p>	 <p>mixture of diastereoisomers</p>	<p>355</p>
<p>190</p>	 <p>mixture of diastereoisomers</p>	<p>369</p>
<p>191</p>	 <p>mixture of diastereoisomers</p>	<p>383</p>






<p>192</p>	 <p>mixture of diastereoisomers</p>	<p>397</p>
<p>193</p>	 <p>mixture of diastereoisomers</p>	<p>367</p>
<p>194</p>	 <p>mixture of diastereoisomers</p>	<p>367</p>
<p>195</p>	 <p>mixture of diastereoisomers</p>	<p>367</p>
<p>196</p>		<p>367</p>





<p>197</p>	 <p>mixture of diastereoisomers</p>	<p>423</p>
<p>198</p>	 <p>diastereoisomer A</p>	<p>417</p>
<p>199</p>	 <p>diastereoisomer B</p>	<p>417</p>
<p>200</p>	 <p>diastereoisomer C</p>	<p>417</p>





<p>201</p>	 <p>diastereoisomer D</p>	<p>417</p>
<p>202</p>	 <p>diastereoisomer A</p>	<p>399</p>
<p>203</p>	 <p>diastereoisomer B and C</p>	<p>399</p>
<p>204</p>	 <p>diastereoisomer D</p>	<p>399</p>





<p>205</p>	 <p>mixture of diastereoisomers</p>	<p>411</p>
<p>206</p>	 <p>mixture of diastereoisomers</p>	<p>401</p>
<p>207</p>	 <p>racemic</p>	<p>373</p>
<p>208</p>	 <p>mixture of diastereoisomers</p>	<p>401</p>
<p>209</p>	 <p>racemic</p>	<p>355</p>






<p>210</p>		<p>355</p>
<p>211</p>	 <p>racemic</p>	<p>383</p>
<p>212</p>		<p>383</p>
<p>213</p>		<p>383</p>
<p>214</p>		<p>383</p>






<p>215</p>	 <p>mixture of diastereoisomers</p>	<p>383</p>
<p>216</p>	 <p>racemic</p>	<p>387</p>
<p>217</p>		<p>327</p>
<p>218</p>		<p>355</p>
<p>219</p>		<p>355</p>





<p>220</p>		<p>355</p>
<p>221</p>		<p>355</p>
<p>222</p>		<p>379</p>
<p>223</p>		<p>407</p>





<p>224</p>	 <p>MeO₂C</p> <p>CO₂Me</p>	<p>495</p>
<p>225</p>	 <p>F</p> <p>mixture of diastereoisomers</p>	<p>367</p>
<p>226</p>	 <p>F</p>	<p>381</p>
<p>227</p>	 <p>F</p>	<p>381</p>






<p>228</p>		<p>479</p>
<p>229</p>		<p>415</p>
<p>230</p>		<p>415</p>
<p>231</p>	 <p style="text-align: center;">mixture of four diastereoisomers</p>	<p>387</p>






<p>232</p>	 <p>mixture of two diastereoisomers</p>	<p>387</p>
<p>233</p>	 <p>single diastereoisomer</p>	<p>387</p>
<p>234</p>		<p>341</p>
<p>235</p>		<p>341</p>
<p>236</p>		<p>353</p>






<p>237</p>		<p>353</p>
<p>238</p>		<p>353</p>
<p>239</p>		<p>353</p>
<p>240</p>		<p>403</p>
<p>241</p>		<p>403</p>





<p>242</p>		<p>403</p>
<p>243</p>		<p>403</p>
<p>244</p>		<p>417</p>
<p>245</p>		<p>417</p>


<p>246</p>		<p>417</p>
<p>247</p>		<p>417</p>
<p>248</p>	 <p style="text-align: right;">diastereoisomer A</p>	<p>371</p>
<p>249</p>	 <p style="text-align: right;">diastereoisomer B</p>	<p>371</p>

<p>250</p>	 <p>diastereoisomer C</p>	<p>371</p>
<p>251</p>	 <p>diastereoisomer D</p>	<p>371</p>
<p>252</p>		<p>341</p>
<p>253</p>	 <p>single diastereoisomer</p>	<p>355</p>
<p>254</p>	 <p>single diastereoisomer</p>	<p>355</p>


<p>255</p>		<p>369</p>
<p>256</p>		<p>369</p>
<p>257</p>	 <p>single diastereoisomer</p>	<p>369</p>
<p>258</p>		<p>369</p>
<p>259</p>	 <p>diastereoisomer A</p>	<p>383</p>

<p>260</p>	 <p>diastereoisomer B</p>	<p>383</p>
<p>261</p>		<p>373</p>
<p>262</p>	 <p>diastereoisomer A</p>	<p>387</p>
<p>263</p>	 <p>diastereoisomer B</p>	<p>387</p>
<p>264</p>	 <p>mixture of diastereoisomers</p>	<p>443</p>


<p>265</p>	 <p>diastereoisomer A</p>	<p>443</p>
<p>266</p>	 <p>diastereoisomer B</p>	<p>443</p>
<p>267</p>		<p>459</p>
<p>268</p>		<p>405</p>

269		505
-----	---	-----

EXAMPLE 270



5




10

A suspension of 10% Pd/C (3.0 mg) in a solution of **EXAMPLE 222** (30.6 mg, 0.0809 mmol) in EtOAc (10 mL) was stirred under 1 atm H₂ for 30 min. The reaction mixture was filtered through Celite and concentrated *in vacuo* to afford **EXAMPLE 270** (29.5 mg, 95%) as a colorless oil. LCMS (ES+) 383 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.45 (2H, dd, *J* 8.9, 4.7 Hz), 7.42 (1H, s), 7.14 (2H, t, *J* 8.4 Hz), 6.16 (1H, br t, *J* 2.0 Hz), 3.67 (1H, dt, *J* 7.6, 4.3 Hz), 3.54 (1H, dt, *J* 7.1, 4.8 Hz), 3.00 (1H, d, *J* 15.2 Hz),



2.54 (2H, m), 2.37 (1H, d, J 15.2 Hz), 2.20 (1H, dt, J 12.8, 10.5 Hz), 1.96 (1H, ddd, J 12.8, 8.3, 2.8 Hz), 1.61 (4H, m); 1.14 (3H, s), 1.04 (3H, t, J 7.6 Hz), 0.97 (3H, t, J 7.6 Hz).

EXAMPLE 271

5




- 10 A suspension of 10% Pd/C (3.0 mg) in a solution of **EXAMPLE 150** (31.8 mg, 0.0679 mmol) in EtOAc (10 mL) was stirred under 1 atm H_2 for 2 h. The reaction mixture was filtered through Celite and concentrated *in vacuo* to afford **EXAMPLE 271** (32.0 mg, quantitative) as a colorless oil. LCMS (ES+) 473 (M+H)⁺; ^1H NMR (CDCl_3 , 500 MHz) δ 7.15-6.95 (10H, br m), 6.12 (1H, br s), 3.78 (1H, m), 3.66 (1H, m), 3.22 (1H, d, J 16.3 Hz), 3.01 (1H, d, J 13.3 Hz), 2.86 (1H, d, J 13.3 Hz), 2.80 (1H, d, J 16.3 Hz), 2.68 (1H, m), 2.36 (1H, d, J 14.6 Hz), 2.02 (1H, m), 1.81 (3H, m), 1.69 (2H, m), 1.62 (2H, m), 1.09 (3H, t, J 7.4 Hz), 0.98 (3H, t, J 7.4 Hz).
- 15

COMPOUND Z5 Step 1:


A solution of the Wieland-Miescher ketone (1.00 g, 5.61 mmol) in glacial acetic acid (20 mL) was
 10 treated with 1,2-ethanedithiol (529 mg, 529 μ L, 5.61 mmol) and a solution of *p*-toluenesulfonic acid (535
 mg, 2.81 mmol) in glacial acetic acid (5 mL). After stirring for 2.5 h, the reaction mixture was poured
 into water. The resulting suspension was extracted with CHCl_3 (3 x 60 mL). The combined organic
 extracts were washed with water (60 mL), 1N aqueous NaOH (60 mL), water (60 mL), brine (60 mL),
 dried (MgSO_4) and concentrated *in vacuo* to afford the crude product (1.49 g). This was purified by
 15 flash chromatography (35 g Si, 40 mL/min, gradient from 0 to 25% EtOAc in hexanes over 30 min,
 isocratic at 25% EtOAc in hexanes for 10 min) to give **COMPOUND W** (1.27g, 89%) as a colorless
 solid. LCMS (ES+) 255 ($\text{M}+\text{H}^+$); ^1H NMR (CDCl_3 , 500 MHz) δ 5.66 (1H, s), 3.34 (3H, m), 3.24 (1H,
 m), 2.61 (1H, tdd, 14.9, 6.3, 1.4 Hz), 2.51 (1H, ttd, *J* 13.7, 4.9, 1.6 Hz), 2.35 (1H, dm, *J* 15.2 Hz), 2.25-
 2.10 (4H, m), 2.01 (1H, m), 1.75 (1H, m), 1.60 (1H, m), 1.29 (3H, d, *J* 1.6 Hz).

20

Step 2:

A solution of **COMPOUND W** (730 mg, 2.87 mmol), (3*R*,4*R*)-1,5-hexadien-3,4-diol (492 mg, 4.31 mmol) and *p*-toluenesulfonic acid (164 mg, 0.862 mmol) in benzene (50 mL) was heated at reflux under a Dean-Stark apparatus for 3 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with saturated NaHCO₃ (50 mL), water (50 mL) and brine (50 mL), dried (MgSO₄) and concentrated *in vacuo* to afford the crude **COMPOUND X** (1.06 g) as a colorless oil. This was used in the next step without any further purification. LCMS (ES+) 351 (M+H)⁺.

Step 3:




A solution of Ti(NO₃)₃·H₂O (1.71 g, 3.85 mmol) in MeOH (200 mL) was added rapidly to a solution of **COMPOUND X** in THF (66 mL) and water (1.3 mL). The turbid mixture was stirred for 1 h and the colorless precipitate produced was removed by filtration. The filtrate was diluted with Et₂O (200 mL) and washed successively with water (100 mL), saturated NaHCO₃ (100 mL) and brine (100 mL), then dried (MgSO₄) and concentrated *in vacuo* to give the crude product (993.9 mg). This was purified by flash chromatography (35 g Si, gradient from 0 to 20% EtOAc in hexanes over 25 min, isocratic at 20% EtOAc in hexanes for 10 min) to give **COMPOUND Y** (374.8 mg, 44%) as a colorless oil. LCMS (ES+) 275 (M+H)⁺; ¹H NMR (CDCl₃, 600 MHz) δ 5.81 (1H, d, *J* 1.9 Hz), 5.80 (1H, ddd, *J* 17.0, 10.2, 6.7 Hz), 5.74 (1H, ddd, *J* 17.0, 10.2, 6.7 Hz), 5.40 (1H, d, *J* 17.0 Hz), 5.32 (1H, d, *J* 17.0 Hz), 5.29 (1H, d, *J* 10.2 Hz), 5.22 (1H, d, *J* 10.2 Hz), 4.17 (1H, t, 7.8 Hz), 4.00 (1H, t, *J* 7.5 Hz), 2.43 (3H, m), 2.29 (2H, m), 1.99 (1H, m), 1.81 (4H, m), 1.36 (3H, s).

15

20

Step 4:

25




COMPOUND Z was synthesized by a method analogous to **COMPOUND G**. LCMS (ES+) 304 (M+H).

5

EXAMPLES

EXAMPLE 272








10





EXAMPLE 272 was synthesized by a method analogous to **EXAMPLE 139**. LCMS (ES+) 375 (M+H)⁺; ¹H NMR (CDCl₃, 500 MHz) δ 7.56 (5H,m), 7.33 (1H, m), 6.30 (1H,s), 5.84 (1H, ddd, *J* 16.8, 10.2, 6.6 Hz), 5.69 (1H, ddd, *J* 16.8, 10.2, 6.6 Hz), 5.40 (1H, d, *J* 16.8 Hz), 5.30 (1H, d, *J* 16.8 Hz), 5.28 (1H, d, *J* 10.2 Hz), 5.21 (1H, d, *J* 10.2 Hz), 4.22 (1H, t, 7.7 Hz), 4.1 (1H, t, *J* 7.7 Hz), 3.20 (1H, d, *J* 15.5 Hz), 2.60 (1H, d, *J* 15.5 Hz), 2.50 (3H, m) 2.30 (2H, m), 1.91 (5H, m), 1.30 (3H, s).





15




The following compounds are synthesized from either enantiopure or racemic hydroxyketone **Z** and commercially available alkyl or aryl hydrazines, using procedures analogous to that described for compounds in the table above:

20


Example	Molecular structure	LCMS (M+1) ⁺
273		376
274		375
275		393
276		389
277		367






<p>278</p>		<p>381</p>
<p>279</p>		<p>432</p>
<p>280</p>		<p>409</p>
<p>281</p>		<p>433</p>


<p>282</p>		<p>462</p>
<p>283</p>		<p>475</p>
<p>284</p>		<p>445</p>
<p>285</p>		<p>405</p>

286		389
287		443
288		419

The following compounds are synthesized from racemic **COMPOUND A** and commercially available alkyl or aryl hydrazines, using procedures analogous to that described for **EXAMPLE 272**:

Example	Molecular structure	LCMS (M+1) ⁺
289		315

<p>290</p>		<p>353</p>
<p>291</p>		<p>324</p>
<p>292</p>		<p>323</p>
<p>293</p>		<p>351</p>
<p>294</p>		<p>352</p>



BIOLOGICAL ASSAYS

5 The activity of the compounds of the present invention regarding glucocorticoid receptor affinity can be evaluated using the following human GR binding assay:

GR Ligand Binding Assay


10 For the hGRI ligand binding assay, cytosols were prepared from recombinant baculovirus expressed receptors. Frozen cell pellets were dounce homogenized in ice cold KPO₄ buffer (10mM KPO₄, 20mM sodium molybdate, 1mM EDTA, 5mM DTT and complete protease inhibitor tablets from Boehringer Mannheim) with a "B" plunger. The homogenates were centrifuged at 35,000 x g for 1 h at 4°C in a JA-20 rotor. The IC₅₀s were determined by incubating the cytosols at a final concentration of 2.5nM [1,2,4,6,7-³H] Dexamethasone in the presence of increasing concentrations (10-11 to 10⁻⁶) of cold dexamethasone or the ligands at 4°C for 24 h. Bound and free were separated by a gel filtration assay, (Geissler et al., personal communication). Half of the reaction was added to a gel filtration plate (MILLIPORE) containing sephadex G-25 beads that was previously equilibrated with KPO₄ buffer containing 1mg/ml BSA and centrifuged at 1000 x g for 5 min.. The reaction plate was centrifuged at 1000 x g for 5 min. and the reactions were collected in a second 96-well plate and scintillation cocktail was added and counted in (Wallac) double coincidence beta counter. The IC₅₀ values were calculated using a 4-parameter fit program.

25 The compounds of this invention demonstrated a range of GR affinity in the above assay with IC₅₀ values between 10 uM and 1 nM. The most advantageous compounds of Formula I and Formula II demonstrated IC₅₀ values between 50 nM and 1 nM.

WHAT IS CLAIMED IS:

1. A compound represented by Formula I or Formula II

5



I

II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

10

m is 0, 1, 2 or 3,

n is 0, 1 or 2;

-A-B-C-D- is selected from the group consisting of:

15

(1) -CH₂-CH₂-CH₂-O-,

(2) -CH₂-CH₂-C(O)-O-,

(3) -CH=CH-C(O)-O-,

(4) -O-CH₂-CH₂-CH₂-,

(5) -O-C(O)-CH₂-CH₂-,

(6) -HC=CH-CH₂-O-,

(7) -CH₂-HC=CH-O-,

20

(8) -CH₂-CH₂-C(O)-NH-,

(9) -CH₂-NH-CH₂-CH₂-,

(10) -CH₂-NH-C(O)-O-,

(11) -NH-C(O)-NH-C(O)-,

(12) -C(O)-NH-C(O)-NH-,

25


(13) -NH-C(O)-NH-CH₂-,

(14) -NH-C(O)-NH-C(=S)-,

(15) -O-CH₂-CH₂-O-,

(16) -S-CH₂-CH₂-S-;

provided that when the atoms at positions B and C of $-A-B-C-D-$ are both carbon atoms, said atoms may be joined together to form a ring selected from



5 X and Y are each independently selected from CH_2 , S and O;

R^1 is selected from the group consisting of:

- 10 (1) C_{1-6} alkyl,
 (2) C_{2-6} alkenyl,
 (3) C_{2-6} akynyl,
 (4) C_{3-6} cycloalkyl,
 (5) aryl,
 (6) $-CH_2$ -phenyl,
 15 (7) HET,

wherein items (1) to (3) above are optionally substituted from one to three substituents independently selected from the group consisting of: halo, OR^5 , and NHR^6 , and items (4) to (7) are optionally substituted with from one to three substituents selected from the group consisting of: halo, OR^5 , NHR^6 ,
 20 C_{1-3} alkyl, C_{2-6} alkenyl, C_{2-6} akynyl;

R^2 and R^3 are each independently selected from the group consisting of:

- 25 (1) hydrogen,
 (2) halo,
 (3) C_{1-6} alkyl,
 (4) C_{2-6} alkenyl,
 (5) C_{2-6} akynyl,
 (6) OR^7 ,
 (7) NHR^8 ,

- (8) aryl,
 (9) -CH₂-phenyl;


R⁵, R⁶, R⁷ and R⁸ are each independently selected from the group consisting of:

- (1) hydrogen,
 (2) methyl;

each R⁴ is independently selected from the group consisting of

- (1) -OH,
 (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected
 10 independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, =S, and halo,
 (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected
 independently from hydroxy, halo and -C(O)-O-C₁₋₂alkyl,
 (4) C₂₋₆alkynyl optionally substituted with 1, 2 or 3 substituents selected
 independently from hydroxy and halo,
 15 (5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently
 from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
 (6) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents
 independently selected from hydroxy, C₁₋₂alkyl and halo,
 (7) -CO₂H,
 20 (8) -CO₂C₁₋₃alkyl,
 (9) -OC₁₋₃alkyl,
 (10) -SO₂-C₁₋₃alkyl,
 (11) -SO₂-phenyl optionally substituted with 1, 2 or 3 substituents independently
 selected from hydroxy, C₁₋₂alkyl and halo
 25 (12) -C₁₋₂alkyl-O-C₁₋₂alkyl,
 (13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,
 (14) -C₁₋₂alkyl-O-phenyl optionally substituted with with 1, 2 or 3 substituents
 independently selected from hydroxy, C₁₋₂alkyl and halo,
 (15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,
 30 (16) 2-(1,3-dioxan)ethyl,
 (17) -C₁₋₂alkyl-C(O)-NH-phenyl,
 (18) -C₁₋₂^{alkyl}-C(O)-NHN,

“with the proviso that the compound of Formula I or Formula II is




5

other than

”.

2. A compound according to claim 1 wherein m is 0, 1 or 2.

3. A compound according to claim 1 wherein n is 0 or 1.
4. A compound according to claim 1 wherein R² and R³ are each individually hydrogen or methyl.
5. A compound according to claim 1 wherein each R⁴ is independently selected from the group consisting of
- (1) -OH,
 - (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, dimethylamino, thio, and halo,
 - (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O-C₁₋₂alkyl,
 - (4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
 - (5) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
 - (6) -SO₂-C₁₋₃alkyl, and
 - (7) -C₁₋₂alkyl-OC₁₋₂alkyl.
6. A compound according to Claim 1 wherein R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:
- (a) halo,
 - (b) OCH₃,
 - (d) CH₃,
 - (e) CN.
7. A compound according to Claim 6 wherein R¹ is phenyl, optionally mono or di-substituted with halo.
8. A compound of Formula I according to claim 1



I

Wherein

m is 0, 1, 2 or 3;

5 n is 0 or 1;

R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- 10 (a) halo,
 (b) OCH₃,
 (d) CH₃,
 (e) CN; and

R² and R³ are each individually hydrogen or methyl.

9. A compound according to claim 8 wherein
 15 Each R⁴ is independently selected from the group consisting of

- (1) -OH,
 (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, thio, and halo,
 20 (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,
 (4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
 (5) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents
 25 independently selected from hydroxy, C₁₋₂alkyl and halo,
 (6) -SO₂-C₁₋₃alkyl, and
 (7) -C₁₋₂alkyl-OC₁₋₂alkyl.


10. A compound according to claim 9 wherein

-A-B-C-D- is selected from the group consisting of:

- (1) -CH₂-CH₂-CH₂-O-,
 (2) -CH=CH-CH₂-O-,
 (3) -CH₂-CH=CH-O-,
 5 (4) -O-CH₂-CH₂-CH₂-,
 (5) -O-CH₂-CH₂-O-,
 (6) -S-CH₂-CH₂-S-,
 (7) -CH₂-NH-CH₂-CH₂-, and
 (8) -CH₂-NH-C(O)-O-;

10 R¹ is phenyl optionally mono or di- substituted with halo.

11. A compound of Formula II according to claim 1



II

15 Wherein

m is 0, 1 or 2;

n is 0 or 1;

R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- 20 (a) halo,
 (b) OCH₃,
 (d) CH₃,
 (e) CN; and

R² and R³ are each individually hydrogen or methyl.

25


12. A compound according to claim 11 wherein


Within this genus, there is a sub-genus of compounds wherein each R⁴ is independently selected from the group consisting of -C₁₋₆alkyl or hydrogen.


13. A compound according to claim 11 wherein X and Y are both O or are both S or X is O and Y is CH₂; R¹ is phenyl optionally mono or di- substituted with halo.


5


14. A compound according to claim 1 selected from the group consisting of






















15. A compound according to claim 1 of the formula



k	R
1	Vinyl
1	Phenyl
1	4-fluorophenyl
2	Benzyl
2	Vinyl
2	Ethyl

5

16. A compound according to claim 1 of the formula







10


k	D	A	C	Ra	Rb
1	O	CH ₂	CH ₂	propyl	Propyl


1	O	CH ₂	CHOH	propyl	Propyl
1	O	CH ₂	CH ₂	allyl	Allyl
1	O	CH ₂	CHOH	allyl	Allyl
1	O	CH ₂	CH ₂	methyl	Methyl
1	O	CH ₂	CHOH	methyl	Methyl
1	O	CH ₂	C(O)	methyl	Methyl
1	O	CH ₂	CH ₂	H	H
1	O	CH ₂	CHOH	H	H
2	CH ₂	O	CH ₂	ethyl	H
2	CH ₂	O	CH ₂	H	Ethyl
2	CH ₂	O	CH ₂	H	Phenyl
2	O	CH ₂	CH(allyl)	allyl	Allyl
2	O	CH ₂	CH ₂	methyl	Methyl
2	O	CH ₂	CH ₂	benzyl	Benzyl
2	O	CH ₂	CH ₂	allyl	Allyl
2	O	CH ₂	CHOH	methyl	Methyl
2	O	CH ₂	CHOH	allyl	Allyl
2	O	CH ₂	CH(allyl)	H	H
2	O	CH ₂	C(O)	methyl	Methyl
2	O	CH ₂	C(O)	allyl	Allyl




17. A compound according to claim 1 of the formula
































Ra
Methyl
Allyl
Isopropyl
2-methoxyethyl
CH ₂ CO ₂ Et
2-(1,3-dioxan)ethyl

20. A compound of the formula





5


C ₁	D ₁	A ₁	B ₁
C(O)	NCH ₃	C(O)	NH
NCH ₂ Ph	C(O)	NCH ₃	C(O)
NCH ₃	C(O)	NCH ₃	C(O)
NCH ₂ CH=CH ₂	C(O)	NCH ₃	C(O)
C(O)	NCH ₃	C(O)	NCH ₂ Ph
C(O)	NCH ₃	C(O)	NCH ₃
C(O)	NCH ₃	C(O)	NCH ₂ CH=CH ₂
C(O)	NCH ₃	C(O)	NH


$N(CH_2)_2CO_2H$	C(O)	NCH_2Ph	C(O)
NH	C(O)	$N(CH_2)_2CO_2H$	C(O)
NH	C(O)	$N(CH_2)_2$ 	C(O)
C(O)	NCH_3	C(O)	$N(CH_2)_2CO_2H$
C(O)	NCH_3	C(O)	$N(CH_2)_2$ 
$NCH_2CH=CH_2$	C(O)	$NCH_2CH=CH_2$	C(O)
NCH_2Ph	C(O)	NCH_2Ph	C(O)
NH	C(S)	NCH_2Ph	C(O)
NH	C(S)	NH	C(O)
NH	C(S)	$NCH_2CH=CH_2$	C(O)
NH	C(S)	NCH_3	C(O)
NH	CH_2	NCH_2Ph	C(O)
NH	CH_2	NH	C(O)
C(O)	NCH_3	CH_2	NCH_3
NH	CH_2	NCH_3	C(O)


21. A compound according to claim 1 for the formula







































































































or a pharmaceutically acceptable salt or hydrate thereof.

22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt or hydrate thereof, in combination with a pharmaceutically acceptable carrier.

5 23. A method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising administering the patient a compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt or hydrate thereof, in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.

10 24. The method according to claim 23, or a pharmaceutically acceptable salt or hydrate thereof, wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of : tissue rejection, leukemias, lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune
15 proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, Little's syndrome, obesity, metabolic syndrome, inflammatory bowel disease, systemic lupus erythematosus,
20 polyartitis nodosa, Wegener's granulomatosis, giant cell arteritis, rheumatoid arthritis, juvenile rheumatoid arthritis, uveitis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, discoid lupus
25 erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, systemic lupus erythematosus, dermatomyositis, herpes gestationis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type I reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitis, erythema nodosum,
30 acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, Human Immunodeficiency Virus (HIV), cell apoptosis, cancer, Kaposi's sarcoma, retinitis pigmentosa, cognitive performance, memory and learning enhancement, depression, addiction, mood disorders, chronic fatigue syndrome, schizophrenia, sleep disorders, and anxiety.

25. The method according to Claim 23 wherein the glucocorticoid receptor mediated disease or condition is selected from the group consisting of tissue rejection, Cushing's syndrome, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, hay fever, allergic rhinitis, asthma, organ transplantation, inflammatory scalp alopecia, psoriasis, discoid lupus erythematosus, and depression.

26. A method of (i) selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a mammal; or (ii) partially or fully antagonizing, repressing agonizing or modulating the glucocorticoid receptor in a mammal, comprising administering to the mammal a compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt or hydrate thereof, in an amount that is effective to modulate the glucocorticoid receptor.

27. Use of a compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt or hydrate thereof, in the manufacture of a medicament for (i) treating a glucocorticoid receptor mediated disease or condition in a mammalian patient; or (ii) selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a mammal; or (iii) partially or fully antagonizing, repressing agonizing or modulating the glucocorticoid receptor in a mammal.

Dated 9 September, 2009

Merck & Co., Inc.

**Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON**